AUTHOR INDEX FOR VOLUME 22

A Brothers, Virginia M. Three Adenylate Cyclase Phenotypes in S49 Lymphoma Cells Produced by Mutations of One Gene, 204 Abell, Creed W. See Denney, Patel, and Fritz, 500 Boyd, Michael R. See Wolf, Statham, McMenamin, Bend, and Phil- Abita, Jean-Pierre. See Gespach, Saal, and Cost, 547 pot, 738 Adams, Stephen M., and Kaminsky, Laurence S. Molecular Orbital Boyle, Michael R. See Hughes, Brown, Taylor, and Insel, 258 Studies of Epoxide Stability of Carcinogenic Polycyclic Aromatic Brothers, Virginia M. See Bourne, Beiderman, and Steinberg, 204 Hydrocarbon Diol Epoxides, 459 Brown, Oliver E. See Seduick, Hamrell, and Laszlo, 766 Adler, A. See Scheibel, 140 Brown, R. Dale. See Hughes, Boyle, Taylor, and Insel, 258 Affolter, Hubert, and Pletscher, Alfred. Storage ofBiogenic Amines Brune, K. See Mehler and Habicht, 525 in Intact Blood Platelets of Man: Dependence on a Proton Gra- Burt, Stanley. See Loeu’, Hashimoto, Williamson, and Anderson, dient, 94 667 Aguilar, Jos#{233} S., Salas, Pedro J. I., and De Robertis, Eduardo. Butcher, R. W. See Clark, Goka, Green, and Barber, 609 Cholinergic Muscannic Receptor in Synaptosomal Membranes:

Heterogeneity of Binding Sites for L-[H]Quinuclidinyl Benzilate, C 304 Aktories, Klaus. See Grandt and Jakobs, 320 Cain, Bruce F. See Baguley, 486 Camus, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and Albuquerque, Edson X. See Maleque, Souccar, and Cohen, 636 Christophe, 342 See Warnick, Jessup, Overman, Eldefrawi, Nimit, and Daly, 565 Caron, Marc G. See De Lean and Kilpatrick, 290 See Warnick, Maleque, Bakry, and Eldefrawi, 82 See Kilpatrick and De Lean, 298 Alvares, Alvito P. See Ueng, 221 Anderson, Wendie. See Loew, Hashimoto, Williamson, and Burt, Carter, Timothy H. See Rose and Leonard, 517 667 Catterall, William A. Andersson, Bo, Nordenskj#{246}ld, Magnus, Rahimtula, Anver, and See Costa, 196 Mold#{233}us, Peter. Prostaglandin Synthetase-Catalyzed Activation See Willow, 627 of Phenacetin Metabolites to Genotoxic Products, 479 Cech, Stella Y., and Maguire, Michael E. Magnesium Regulation of the Beta-Receptor-Adenylate Cyclase Complex. I. Effects of Man- Asao, Yukari. See Suketa, Yamada, and Hasegawa, 116 Aslaman, Dimitrina, and de Cheveign#{233}, Suzanne. Inelastic Elec- ganese on Receptor Binding and Cyclase Activation, 267 tron Tunneling Spectroscopic Study of Interaction of Acetylcho- Chatelain, P., Robberecht, P., Waelbroeck, M., De Neef, P., Ca- line and ,G-Methyl Acetylcholine with Alumina Surface, 678 mus, J., and Christophe, J. Thermodependence of Guanine Nucleotide-Activated Rat Cardiac Adenylate Cyclase Activity: Ef- fect of Cholera Toxin Pretreatment, 342 B Cheney, B. V., Lahti, R. A., Barsuhn, C., and Gay, D. D. An Bader, Hermann. See Gietzen and W#{252}thrich, 413 Analysis of Binding at the Opioid Receptor Based upon an Ago- Baguley, Bruce C., and Cain, Bruce F. Comparison of the in Vito nist/Antagonist Two-State Model, 349 and in Vitro Antileukemic Activity ofMonosubstituted Derivatives Cho, A. K. See Duncan, 235 of 4’-(9-Acridinylamino)methanesulfon-m-anisidide, 486 Cho, Arthur K., Maynard, Michael S., Matsumoto, Richard M., Bakry, Nabil Lindeke, Bj#{246}rn, Paulsen, Ulla, and Miwa, Gerald T. The Eldefrawi, Ainira T., Eldefrawi, Mohyee E., and Riker, Walter Opposing Effects of N-Hydroxyamphetamine and N-Hydroxy- F., Jr. Interactions of Quaternary Ammonium Drugs with Acetyl- phentermine on the H2O2 Generated by Hepatic Cytochrome P- cholinesterase and Acetyicholine Receptor of Torpedo Electric 450, 465 Organ, 63 Christophe, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and See Warnick, Maleque, Eldefrawi, and Albuquerque, 82 Camus, 342 Barber, R. See Clark, Goka, Green, and Butcher, 609 Chwang, T. Ling. See Roberts, Franklin, Odom, and Peck, 760 Barsuhn, C. See Cheney, Lahti, and Gay, 349 Clark, R. B., Goka, T. J., Green, D. A., Barber, R., and Butcher, Batzri, Shmuel R. W. Differences in the Forskolin Activation of Adenylate Cy- Harmon, John W., and Thompson, William F. Interaction of clases in Wild-Type and Variant Lymphoma Cells, 609 Histamine with Gastric Mucosal Cells: Effect of Histamine Ago- Clark-Rosenberg, Reena. See Marangos, Patel, and Boulenger, 26 nists on Binding and Biological Response, 33 Clement-Cormier, Yvonne C. See Suen and Kwan, 595 Harmon, John W., Dyer, Jean, and Thompson, William F. Cohen, Jonathan B. See Maleque, Souccar, and Albuquerque, 636 Interaction of Histamine with Gastric Mucosal Cells: Effect of Coffins, Allan C. See Marks, 554 Histamine H2 Antagonists on Binding and Biological Response, 41 Conney, Allen H. See Vyas, Levin, Yagi, Thakker, Ryan, Thomas, Baxter, Diane. See Fischer, 231 and Jerina, 182 Beaujouan, J. C., Torrens, Y., Herbet, A., Daguet, M.-C., Glow- Conway, J. G., Kauffman, F. C., Ji, S., and Thurman, R. G. Rates inski, J., and Proehiantz, A. Specific Binding of an Immuno- of Sulfation and Glucuronidation of 7-Hydroxycoumarin in Pen- reactive and Biologically Active ‘251-Labeled Substance P Deriva- portal and Pericentral Regions of the Liver Lobule, 509 tive to Mouse Mesencephalic Cells in Primary Culture, 48 Cost, H#{233}l#{232}ne.See Gespach, Saal, and Abita, 547 Beiderman, Barry. See Bourne, Steinberg, and Brothers, 204 Costa, Maria R., and Catterall, William A. Characterization of Bend, John R. See Wolf, Statham, McMenamin, Boyd, and Philpot, Variant Neuroblastoma Clones with Missing or Altered Sodium 738 Channels, 196 Boulenger, Jean-Philippe. See Marangos, Patel, and Clark-Rosen- Covey, Douglas F. See Klunk and Ferrendelli, 431, 438, 444 berg, 26 Crippen, Gordon M. Distance Geometry Analysis of the Benzodiaze- Bourne, Henry R., Beiderman, Barry, Steinberg, Florence, and pine Binding Site, 11

803 804 AUTHOR IN1)EX

Crooke, Stanley T. See Long, Willis, and Prestayko, 152 Line HL-60: Comparison with Human Peripheral Neutrophils, 547 Gewirtz, David A., Randolph, Joyce K., and Goldman, I. David. D Catecholamine-Induced Release of the Folic Acid Analogue, Meth- Daguet, M.-C. See Beaujouan, Torrens, Herbet, Glowinski, and Pro- otrexate, from Rat Hepatocytes in Suspension: An Alpha-Adre- chiantz, 48 nergic Phenomenon, 493 Dalmark, Mads, and Johansen, Peter. Molecular Association be- Gietzen, Klaus, W#{252}thrich, Andreas, and Bader, Hermann. Effects tween Doxorubicin (Adriamycin) and DNA-Derived Bases, Nu- of Microtubular Inhibitors on Plasma Membrane Calmodulin-De- cleosides, Nucleotides, Other Aromatic Compounds, and Proteins pendent Ca2-Transport ATPase, 413 in Aqueous Solution, 158 Glaumann, Hans. See Thomas, Ryan, von Bahr, and Levin, 190 Daly, John W. See Warnick, Jessup, Overman, Eldefrawi, Nimit, Glowinski, J. See Beaujouan, Torrens, Herbet, Daguet, and Pro- and Albuquerque, 565 chiantz, 48 Dannan, Ghazi A., and Guengerich, F. Peter. Immunochemical Goka, T. J. See Clark, Green, Barber, and Butcher, 609 Comparison and Quantitation of Microsomal Flavin-Containing Goldman I. David. See Gewirtz and Randolph, 493 Monooxygenases in Various Hog, Mouse, Rat, Rabbit, Dog, and Goren, H. J. See Hanif, Hollenberg, and Lederis, 381 Human Tissues, 787 Gorissen, H. See Ilien and Laduron, 243 Dax, Elizabeth M., and Partilla, John S. Adrenergic Ligand Lipo- Grandt, R#{252}diger, Aktories, Klaus, and Jakobs, Karl H. Guanine solubiity in Membranes: Direct Assessment in a Beta-Adrenergic Nucleotides and Monovalent Cations Increase Agonist Affinity of Binding System, 5 Prostaglandin E2 Receptors in Hamster Adipocytes, 320 de Cheveign#{233}, Suzanne. See Aslanian, 678 Green, D. A. See Clark, Goka, Barber, and Butcher, 609 De Lean, Andre Gruenwedel, Dieter W., and Diaham, Babou. Methylmercury(II)- Kilpatrick, Brian F., and Caron, Marc G. Dopamine Receptor of Induced Histone Perturbations in Nuclei Isolated from Calf Thy- the Porcine Anterior Pituitary Gland: Evidence for Two Affinity mus, 121 States Discriminated by Both Agonists and Antagonists, 290 Grunewald, Gary L. See Rafferty, 127 See Kilpatrick and Caron, 298 Guengerich, F. Peter. See Dannan, 787 See Vale, Lefkowitz, and Stadel, 619 Gylfe, Erik, and Heliman, Bo. Lack of Ca2 Ionophoretic Activity of De Neef, P. See Chatelain, Robberecht, Waelbroeck, Camus, and Hypoglycemic Sulfonylureas in Excitable Cells and Isolated Secre- Christophe, 342 tory Granules, 715 Denney, Richard M., Patel, Nutan T., Fritz, Richard R., and Abell, Creed W. A Monoclonal Antibody Elicited to Human H

Platelet Monoamine Oxidase: Isolation and Specificity for Human Habicht, J. See Mehier and Brune, 525 Monoamine Oxidase B but Not A, 500 Hamrell, Michael. See Sedwick, Brown, and Laszlo, 766 De Robertis, Eduardo. See Aguilar and Salas, 304 Hamf, K., Goren, H. J., Hollenberg, M. D., and Lederis, K. Oxy- Diaham, Babou. See Gruenwedel, 121 tocin Action: Mechanisms for Insulin-Like Activity in Isolated Rat Duncan, J. D., and Cho, A. K. N-Oxidation of Phentermine to N- Adipocytes, 381 Hydroxyphentermine by a Reconstituted Cytochrome P-450 Oxi- Harden, T. Kendall. See Meeker, 310 dase System from Rabbit Liver, 235 Harmon, John W. Dyer, Jean. See Batzri, Harmon, and Thompson, 41 See Batzri and Thompson, 33 See Batzri, Dyer, and Thompson, 41 E Harrelson, Willard G., Jr., and Mason, Ronald P. Microsomal Eldefrawi, Amira T. Reduction of Gentian Violet: Evidence for Cytochrome P-450- Miller, E. Roxanne, Murphy, Deidre L., and Eldefrawi, Mohyee Catalyzed Free Radical Formation, 239 E. [‘H]Phencyclidine Interactions with the Nicotinic Acetylcholine Harris, R. Adron. See Stokes, 99 Receptor Channel and Its Inhibition by Psychotropic, Antipsy- Hasegawa, Jun. See Suketa, Yamada, and Asao, 116 chotic, Opiate, Antidepressant, Antibiotic, Antiviral, and Antiar- Hashimoto, Gail. See Loew, Williamson, Burt, and Anderson, 667 rhythmic Drugs, 72 Helhnan, Bo. See Gylfe, 715 See Bakry, Eldefrawi, and Riker, 63 Herbet, A. See Beaujouan, Torrens, Daguet, Glowinski, and Pro- See Warnick, Maleque, Bakry, and Albuquerque, 82 chiantz, 48 Eldefrawi, Mohyee E. Hidaka, Hiroyoshi See Bakry, Eldefrawi, and Riker, 63 See Tanaka and Ohmura, 403 See Eldefrawi, Miller, and Murphy, 72 See Tanaka, Ohmura, and Yamakado, 408 See Warnick, Jessup, Overman, Nimit, Daly, and Albuquerque, 565 Hirsch, James D. See Kochman, 335 Epand, Richard M. Cation-Induced Conformational Change in Glu- Hnatowich, Mark, and LaBella, Frank S. Light-Enhanced Inhibi- cagon, 105 tion of Ouabain Binding to Digitalis Receptor in Rat Brain and Erickson, Leonard C. See Ramonas and McManus, 175 Guinea Pig Heart by the Food Dye Erythrosine, 687 Hollenberg, M. D. See Hanif, Goren, and Lederis, 381 F Hom, D. S. See Law and Loh, 1 Fain, John N. See Litosch, Hudson, Mills, and Li, 109 Houghton, Janet A., Tice, Arvil J., and Houghton, Peter J. The Ferrendelli, James A. See Kiunk and Covey, 431, 438, 444 Selectivity of Action of Methotrexate in Combination with 5- Fischer, Paul H., and Baxter, Diane. Enzyme Regulatory Site- Fluorouracil in Xenografts of Human Colon Adenocarcinomas, 771 Directed Drugs: Modulation of Thymidine Triphosphate Inhibi- Houghton, Peter J. See Houghton and Tice, 771 tion of Thymidine Kinase by 5’-Amino-5’-deoxythymidine, 231 Hudson, Thomas H. See Litosch, Mills, Li, and Fain, 109 Franklin, Paula. See Roberts, Odom, Peck, and Chwang, 760 Hughes, Richard J., Boyle, Michael, R., Brown, R. Dale, Taylor, Fritz, Richard R. See Denney, Pate!, and Abel!, 500 Palmer, and Insel, Paul A. Characterization of Coexisting Al- pha,- and Beta2-Adrenergic Receptors on a Cloned Muscle Cell G Line, BC3H-1, 258

Gay, D. D. See Cheney, Lahti, and Barsuhn, 349 Gespach, Christian, Saal, Fortuna, Cost, H#{233}l#{232}ne,and Abita, Jean-Pierre. Identification and Characterization of Surface Re- men, B., Gorissen, H., and Laduron, P. M. Characterization of ceptors for Histamine in the Human Promyelocytic Leukemia Cell Solubiized Serotonin (S2) Receptors in Rat Brain, 243 AUTHOR INDEX 805

Insel, Paul A. Levin, Wayne See Hughes, Boyle, Brown, and Taylor, 258 See Thomas, Ryan, von Bahr, and Glaumann, 190 See Snavely, 532 See Vyas, Yagi, Thakker, Ryan, Thomas, Conney, and Jerina, 182 Li, Shih-Ying. See Litosch, Hudson, Mills, and Fain, 109 J Lindeke, Bj#{246}rn. See C/to, Maynard, Matsumoto, Paulsen, and Miwa,

Jakobs, Karl H. See Grandt and Aktories, 320 465 Jefcoate, Colin R. See Keller and Turner, 451 Litosch, Irene, Hudson, Thomas H., Mills, Ira, Li, Shih-Ying, and Jerina, Donald M. See Vyas, Levin, Yagi, Thakker, Ryan, Thomas, Fain, John N. Forskolin as an Activator of Cyclic AMP Accu- and Conney, 182 mulation and Lipolysis in Rat Adipocytes, 109 Jessup, Peter J. See Warnick, Overman, Eldefrawi, Nimit, Daly, Loew, Gilda, Hashimoto, Gail, Williamson, Lenita, Burt, Stanley, and Albuquerque, 565 and Anderson, Wendie. Conformational-Energy Studies of Ji, S. See Conway, Kauffman, and Thurman, 509 Tetrapeptide Opiates: Candidate Active and Inactive Conforma- Johansen, Peter. See Dalmark, 158 tions, 667 Johnston, Colin I. See Woodcock, 589 Loh, H. H. See Law and Hom, 1 Joost, Hans-Georg, and Steinfelder, Hans-Jurgen. Modulation of Lombardini, John B. See Sufrmn, 752 Insulin Sensitivity by Adenosine: Effects on Glucose Transport, Long, Byron H., Willis, Charles E., Prestayko, Archie W., and Lipid Synthesis, and Insulin Receptors of the Adipocyte, 614 Crooke, Stanley T. Effect of Anthracycline Analogues on the Appearance of Newly Synthesized Total RNA and Messenger

K RNA in the Cytoplasm of Erythroleukemia Cells, 152 Lucier, George W. See Lui, Slaughter, and Philpot, 795 Kaiser, E. T. See Taylor and Miller, 657 Lui, Edmund M. K., Slaughter, Shelley R., Philpot, Richard M., Kaminsky, Laurence S. See Adams, 459 and Lucier, George W. Endocrine Regulation of Cadmium-Sen- Kanter, Peter M., and Schwartz, Herbert S. A Fluorescence En- sitive Cytochrome P-450 in Rat Liver, 795 hancement Assay for Cellular DNA Damage, 145 Lukovits, Istv#{225}n. A Theorem on de Novo Group Contributions, 725 Kauffman, F. C. See Conway, Ji, and Thurman, 509 Kellar, Kenneth J. See Schwartz and McGee, 56 Keller, Gabriela M., Turner, Chris R., and Jefcoate, Colin R. M Kinetic Determinations of Benzo[a]pyrene Metabolism to Dihy- driol Epoxides by 3-Methylcholanthrene-Induced Rat Liver Micro- MacDonald, Timothy, L. See Tachizau’a and Neal, 745 somes, 451 Macfarlane, Donald E. Kenimer, James G. See McGee, 360 Bidirectional Collision Coupling in the Regulation of the Adenylate Kharasch, Evan D., and Novak, Raymond F. Inhibition of Micro- Cyclase: The Allozyme Hypothesis for Receptor Function, 580 somal Oxidative Drug Metabolism by 1,4-Bis{2-[2- and Stump, David C. Parallel Observation of the Occupancy of the hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione Diace- Alpha2-Adrenergic Receptor in Intact Platelets and Its Ability to tate, a New Antineoplastic Agent, 471 Inhibit the Adenylate Cyclase, 574 Kilpatrick, Brian F. Mackenzie, Peter. See Peura, Koivusaari, and Lang, 721 De Lean, Andre, and Caron, Marc G. Dopamine Receptor of the Maguire, Michael E. Porcine Anterior Pituitary Gland: Effects of N-Ethylmaleimide Magnesium Regulation of the Beta-Receptor-Adenylate Cyclase and Heat on Ligand Binding Mimic the Effects of Guanine Nu- Complex. II. Sc35 as a Mg2 Antagonist, 274 cleotides, 298 See Cech, 267 See De Lean and Caron, 290 M#{228}hlmann, Horst. See Quast and Vollmer, 20 Kioss, Michelle W. See Rosen and Rauckman, 529 Maleque, Mohammed A. Kiunk, Wiffiam E. Souccar, Caden, Cohen, Jonathan B., and Albuquerque, Edson Covey, Douglas F., and Ferrendelli, James A. Anticonvulsant x. Meproadifen Reaction with the Ionic Channel of the Acetyl- choline Receptor: Potentiation of Agonist-Induced Desensitization Properties of a-, .‘-, and a,y-Substituted y-Butyrolactones, 438 Covey, Douglas F., and Ferrendeffi, James A. Comparison of at the Frog Neuromuscular Junction, 636 Epileptogenic Properties of Unsubstituted and fl-Alkyl-Substi- See Warnick, Bakry, Eldefrawi, and Albuquerque, 82 tuted y-Butyrolactones, 431 Malincomco, Scott M., and McCarl, Richard L Effect of Halothane Covey, Douglas F., and Ferrendeffi, James A. Structure-Activity on Cardiac Sarcoplasmic Reticulum Ca2-ATPase at Low Calcium Relationships of Alkyl-Substituted y-Butyrolactones and Succini- Concentrations, 8 mides, 444 Marangos, Paul J., Patel, Jitendra, Boulenger, Jean-Philippe, Kochman, Ronald L., and Hirsch, James D. Thermodynamic and Clark-Rosenberg, Reena. Characterization of Peripheral- Changes Associated with Benzodiazepine and Alkyl f3-Carboline- Type Benzodiazepine Binding Sites in Brain Using [‘H]Ro 5-4864, 3-carboxylate Binding to Rat Brain Homogenates, 335 26 Koivusaari, Ulla. See Peura, Mackenzie, and Lang, 721 Maren, Thomas H. See Sanyal, Swenson, and Pessah, 211 Kwan, Peter C. K. See Suen and Clement-Cormier, 595 Marks, Michael J., and Collins, Allan C. Characterization of Nico- tine Binding in Mouse Brain and Comparison with the Binding of

L a-Bungarotoxin and Quinuclidinyl Benzilate, 554 Markstein, R. See Seiler, 281 LaBella, Frank S. See Hnatowich, 687 Mason, Ronald P. Laduron, P. M. See Ilien and GorLssen, 243 See Harrelson, 239 Lahti, R. A. See Cheney, Barsuhn, and Gay, 349 See Mottley and Trice, 732 Lang, Matti. See Peura, Mackenzie, and Koivusaari, 721 Matsumoto, Richard M. See Cho, Maynard, Lindeke, Paulsen, and Laszlo, John See Sedwick, Hamrell, and Brown, 766 Miwa, 465 Law, P. Y., Horn, D. S., and Loh, H. H. Loss of Opiate Receptor Maynard, Michael S. See Cho, Matsumoto, Lindeke, Paulsen, and Activity in Neuroblastoma x Glioma NG1O8-15 Hybrid Cells after Miwa, 465 Chronic Opiate Treatment: A Multiple-Step Process, 1 McCarl, Richard L. See Malinconico, 8 Lederis, K. See Hanif, Goren, and Hollenberg, 381 McGee, Richard, Jr. Lefl(owitz, Robert J. See Vale, De Lean, and Stadel, 619 and Kenimer, James G. The Effects of Exposure to Unsaturated Leonard, Thomas B. See Rose and Carter, 517 Fatty Acids on Opiate Receptors, Prostaglandin E, Receptors, and 806 AUTHOR INDEX

McGee, Richard, Jr.-continued Philpot, Richard M. and Kenimer, James G.-continued See Lui, Slaughter, and Lucier, 795 Adenylate Cyclase Activity of Neuroblastoma x Glioma Hybrid See Wolf, Statham, McMenamin, Bend, and Boyd, 738 Cells, 360 Pletscher, Alfred. See Affolter, 94 See Schwartz and Kellar, 56 Prestayko, Archie W. See Long, Willis, and Crooke, 152 McManus, Michael E. See Ramonas and Erickson, 175 Prochiantz, A. See Beaujouan, Torrens, Herbet, Daguet, and Glow- McMenamin, Mary G. See Wolf, Statham, Bend, Boyd, and Phi Ipot, inski, 48 738 Meeker, Rick B., and Harden, T. Kendall. Muscarinic Cholinergic Q

Receptor-Mediated Activation of Phosphodiesterase, 310 Quast, Ulrich, M#{228}hlmann, Horst, and Vollmer, Karl-Otto. Tem- Mehler, E. L., Habicht, J., and Brune, K. Quantum Chemical perature Dependence of the Benzodiazepine-Receptor Interaction, Analysis of Structure-Activity Relationships in Nonsteroidal Anti- 20 inflammatory Drugs, 525 Quastel, David M. J. See Pennefather, 369 Miller, E. Roxanne. See Eldefrawi, Murphy, and Eldefrawi, 72 Miller, Richard J. See Taylor and Kaiser, 657 R Mills, Ira. See Litosch, Hudson, Li, and Fain, 109 Rafferty, Michael F., and Grunewald, Gary L. The Remarkable Miwa, Gerald T. See Cho, Maynard, Matsumoto, Lindeke, and Paul- Substrate Activity for Phenylethanolamine N-Methyltransferase sen, 465 of Some Conformationally Defined Phenylethylamines Lacking a Mold#{233}us, Peter. See Andersson, Nordenskjdld, and Rahimtula, 479 Side-Chain Hydroxyl Group: Conformationally Defined Adrener- Mottley, Carolyn, Trice, Thomas B., and Mason, Ronald P. Direct gic Agents. 6, 127 Detection of the Sulfur Trioxide Radical Anion during the Horse- Rahimtula, Anver. See Andersson, Nordenskj#{244}ld, and Mold#{233}us, 479 radish Peroxidase-Hydrogen Peroxide Oxidation of Sulfite Ramonas, Lori M., Erickson, Leonard C., and McManus, Michael (Aqueous Sulfur Dioxide), 732 E. The Effect of Misonidazole on the Cytotoxicity and DNA Cross- Murphy, Deirdre L. See Eldefrawi, Miller, and Eldefrawi, 72 Linking Activity of an Activated SuliIdocyclophosphamide in Hy- Murphy, Kenneth M. M., and Snyder, Solomon H. Heterogeneity poxic Mouse Leukemia Cells, 175 of Adenosine A, Receptor Binding in Brain Tissue, 250 Randolph, Joyce K. See Gewirtz and Goldman, 493 Rauckman, Elmer J. See Rosen and Kioss, 529 N Rautanen, P. K. See Vohra, 602 Nadler, Hana. See Nehmad and Simantov, 389 Retz, Konrad C., and Steele, William J. Mechanism of Inhibition of Neal, Robert A. See Tachizawa and MacDonald, 745 Protein Synthesis by Morphine in Rat Brain and Liver, 706 Nebert, Daniel W. See Tukey and Negishi, 779 Riker, Walter F., Jr. See Bakry, Eldefrawi, and Eldefrawi, 63 Negishi, Masahiko. See Tukey and Nebert, 779 Robberecht, P. See Chatelain, Waelbroeck, De Neef, Camus, and Nehmad, Rafael, Nadler, Hana, and Simantov, Rabi. Effects of Christophe, 342 Acute and Chronic Morphine Treatment on Calmodulin Activity Roberts, DeWayne, Franklin, Paula, Odom, Gina, Peck, Charles, of Rat Brain, 389 and Chwang, T. Ling. Cytotoxicity of 5-Fluoro-5’-O-nitro-2’-de- Nimit, Yuth. See Warnick, Jessup, Overman, Eldefrawi, Daly, and oxyuridine, a New Fluorinated Pyrimidine Derivative, in L1210 Albuquerque, 565 Cultures, 760 Nordenskj#{246}ld, Magnus. See Andersson, Rahimtula, and Mold#{233}us, Rose, Kathleen M., Leonard, Thomas B., and Carter, Timothy H. 479 Effects of Adenine Nucleosides on RNA Synthesis in Adenovirus- Norman, Jon A., and Staehlin, Mattys. Calmodulin Inhibitors Ac- Infected Cells: 9-fl-D-Arabinofuranosyladenine as a Selective In- tivate Glycogen Phosphorylase B to A Conversion in C6 Glioma hibitor of RNA Polyadenylation, 517 Cells, 395 Rosen, Gerald M., Kloss, Michelle W., and Rauckman, Elmer J. Novak, Raymond F. See Kharasch, 471 Initiation of in Vitro Lipid Peroxidation by N-Hydroxynorcocaine and Norcocaine Nitroxide, 529 0 Rowe, Elizabeth S. The Effects of Ethanol on the Thermotropic

Odom, Gina. See Roberts, Franklin, Peck, and C/twang, 760 Properties of Dipalmitoylphosphatidylcholine, 133 Ohmura, Takehisa Ryan, Dene E. See Tanaka and Hidaka, 403 See Thomas, von Bahr, Glaumann, and Levin, 190 See Tanaka, Yamakado, and Hidaka, 408 See Vyas, Levin, Yagi, Thakker, Thomas, Conney, and Jerina, 182 Overman, Larry E. See Warnick, Jessup, Eldefrawi, Nimit, Daly, S and Albuquerque, 565 Saal, Fortuna. See Gespach, Cost, and Abita, 547 P Saederup, Else. See Squires, 327 Partilla, John S. See Dax, 5 Salas, Pedro J. I. See Aguilar and De Robertis, 304 Patel, Jitendra. See Marangos, Boulenger, and Clark-Rosenberg, 26 Sanyal, Gautam, Swenson, Erik R., Pessah, Ness I., and Maren, Patel, Nutan T. See Denney, Fritz, and Abel!, 500 Thomas H. The Carbon Dioxide Hydration Activity of Skeletal Paulsen, Ulla. See Cho, Maynard, Matsumoto, Lindeke, and Miwa, Muscle Carbonic Anhydrase: Inhibition by Sulfonamides and An- 465 ions, 211 Peck, Charles. See Roberts, Franklin, Odom, and Chwang, 760 Scheibel, L. W., and Adler, A. Antimalarial Activity of Selected Pennefather, Peter, and Quastel, David M. J. Modification of Dose- Aromatic Chelators. III. 8-Hydroxyquinolines (Oxines) Substituted Response Curves by Effector Blockade and Uncompetitive Antag- in Positions 5 and 7, and Oxines Annelated in Position 5,6 by an onism, 369 Aromatic Ring, 140 Perez, David J., and Tattersall, Martin H. N. The Metabolic Basis Schwartz, Herbert S. See Kanter, .145 of Deoxyuridine Cytotoxicity: Studies of Cultured Human Lym- Schwartz, Rochelle D., McGee, Richard, Jr., and Kellar, Kenneth phoblasts, 166 J. Nicotinic Cholinergic Receptors Labeled by [3H]Acetylcholine Pessah, Ness I. See Sanyal, Swenson, and Maren, 211 in Rat Brain, 56 Peura, Pekka, Mackenzie, Peter, Koivusaari, Ulla, and Lang, Sedwick, W. David, Hamrell, Michael, Brown, Oliver E., and Matti. Increased Fluidity of a Model Membrane Caused by Tet- Laszlo, John. Metabolic Inhibition by a New Antifolate, 2,4- rahydro-f.?-Carbolines, 721 Diamino-6- (2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]py- AUTHOR INDEX 807

rimidine (BW3O1U), an Effective Inhibitor of Human Lymphoid Thompson, Wiffiam F. and Dihydrofolate Reductase-Overproducing Mouse Cell Lines, See Batzri and Harmon, 33 766 See Batzri, Harmon, and Dyer, 41 Seiler, M. P., and Markstein, R. Further Characterization of Struc- Thurman, R. G. See Conway, Kauffman, and Ji, 509 tural Requirements for Agonists at the Striatal Dopamine D-1 Tice, Arvil J. See Houghton and Houghton, 771 Receptor: Studies with a Series of Monohydroxyaminotetralins on Tolkovsky, A. M. Etorphine Binds to Multiple Opiate Receptors of Dopamine-Sensitive Adenylate Cyclase and a Comparison with the Caudate Nucleus with Equal Affinity but with Different Ki- Dopamine Receptor Binding, 281 netics, 648 Simantov, Rabi. See Nehmad and Nadler, 389 Torrens, Y. See Beaujouan, Herbet, Daguet, Glou’inski, and Pro- Slaughter, Shelley R. See Lui, Philpot, and Lucier, 795 chiantz, 48 Snavely, Marshall D., and Insel, Paul A. Characterization of Alpha- Trice, Thomas B. See Mottley and Mason, 732 Adrenergic Receptor Subtypes in the Rat Renal Cortex: Differen- Tukey, Robert H., Negishi, Masahiko, and Nebert, Daniel W. tial Regulation of Alpha1- and Alpha2-Adrenergic Receptors by Quantitation of Hepatic Cytochrome P-450 with the Use of a Guanyl Nucleotides and Na, 532 Cloned DNA Probe: Effects of Various P-450 Inducers in C57BL/ Snyder, Solomon H. See Murphy, 250 6N and DBA/2N Mice, 779 Souccar, Caden. See Maleque, Cohen, and Albuquerque, 636 Turner, Chris R. See Keller and Jefcoate, 451 Squires, Richard F., and Saederup, Else. -y-Aminobutyric Acid Receptors Modulate Cation Binding Sites Coupled to Independent U Benzodiazepine, Picrotoxin, and Anion Binding Sites, 327 Stadel, Jeffrey M. See Vale, De Lean, and Lefkowitz, 619 Ueng, Tzuu-Huei, and Alvares, Alvito P. Pulmonary Cytochromes Staehlin, Mattys. See Norman, 395 P-450 from Rabbits Treated with 3-Methylcholanthrene, 221 Statham, Charles N. See Wolf, McMenamin, Bend, Boyd, and Phil- pot, 738 V Steele, William J. See Retz, 706 Steinberg, Florence. See Bourne, Beiderman, and Brothers, 204 Vale, Ronald D., De Lean, Andre, Lefkowitz, Robert J., and Steinfelder, Hans-Jurgen. See Joost, 614 Stadel, Jeffrey M. Regulation of Insulin Receptors in Frog Eryth- Stokes, James A., and Harris, R. Adron. Alcohols and Synaptoso- rocytes by Insulin and Concanavalin A: Evidence for Discrete mal Calcium Transport, 99 Classes of Insulin Binding Sites, 619 Stump, David C. See Macfarlane, 574 Vohra, M. M., and Rautanen, P. K. Pharmacological Characteriza- Suen, Erick T., Kwan, Peter C. K., and Clement-Cormier, Yvonne tion of Histamine Receptors Mediating Cyclic AMP Accumulation C. Selective Effects of an Essential Suithydryl Group on the in the Mouse Vas Deferens: Sensitivity to H1 and H2 Receptor Activation of Dopamine- and Guanine Nucleotide-Sensitive Ade- Agonists and Antagonists, 602 nylate Cyclase, 595 Volliner, Karl-Otto. See Quast and Mdhlmann, 20 Sufrmn, Janice R., and Lombardini, John B. Differences in the von Bahr, Christer. See Thomas, Ryan, Glaumann, and Levin, 190 Active-Site Region of Tumor versus Normal Isozymes of Mars- Vyas, Kamlesh P., Levin, Wayne, Yagi, Haruhiko, Thakker, malian ATP:L-Methionine S-Adenosyltransferase, 752 Dhiren R., Ryan, Dene E., Thomas, Paul E., Conney, Allen Suketa, Yasunobu, Yamada, Masakazu, Hasegawa, Jun, and H., and Jerina, Donald M. Stereoselective Metabolism of the Asao, Yukari. A Possible Mechanism for Elevation of Glucose-6- (+)- and (-)-Enantiomers of trans-1,2-Dthydroxy-1,2-Dihydro- Phosphatase Activity in Kidney and Liver of Fluoride-Treated chrysene to Bay-Region 1,2-Diol-3,4-Epoxide Diastereomers by Rats, 116 Rat Liver Enzymes, 182 Swenson, Erik R. See Sanyal, Pessah, and Maren, 211 W

T Waelbroeck, M. See Chatelain, Robberecht, De Neef, Camus, and Tachizawa, Haruo, MacDonald, Timothy L., and Neal, Robert A. Christophe, 342 Rat Liver Microsomal Metabolism of Propyl Halides, 745 Warnick, Jordan E. Tanaka, Toshio Jessup, Peter J., Overman, Larry E., Eldefrawi, Mohyee E., Ohmura, Takehisa, and Hidaka, Hiroyoshi. Hydrophobic Inter- Nimit, Yuth, Daly, John W., and Albuquerque, Edson X. action of the Ca2-Calmodulin Complex with Calmodulin Antago- Pumiiotoxin-C and Synthetic Analogues: A New Class of Nicotinic fists: Naphthalenesulfonamide Derivatives, 403 Antagonists, 565 Ohmura, Takehisa, Yamakado, Toshiyuki, and Hidaka, Hiro- Maleque, Mohammed A., Bakry, Nabil, Eldefrawi, Amira T., yoshi. Two Types of Calcium-Dependent Protein Phosphoryla- and Albuquerque, Edson X. Structure-Activity Relationships of tions Modulated by Calmodulin Antagonists: Naphthalenesulfon- Amantadine. I. Interaction of the N-Alkyl Analogues with the amide Derivatives, 408 Ionic Channels of the Nicotonic Acetylcholine Receptor and Elec- Tank, A. W., and Weiner, N. Induction of Tyrosine Hydroxylase by trically Excitable Membrane, 82 Glucocorticoids in Mouse Neuroblastoma Cells: Enhancement of Weiner, N. See Tank, 421 the Induction by Cyclic AMP, 421 Williamson, Lenita. See Loew, Hashimoto, Burt, and Anderson, 667 Tattersall, Martin H. N. See Perez, 166 Wiffis, Charles E. See Long, Prestayko, and Crooke, 152 Taylor, John W., Miller, Richard J., and Kaiser, E. T. Structural Willow, Max, and Catterall, William A. Inhibition of Binding of Characterization of $-Endorphin through the Design, Synthesis, [3H]Batrachotoxinin A 20-a-Benzoate to Sodium Channels by the and Study of Model Peptides, 657 Anticonvulsant Drugs Diphenythydantoin and Carbamazepine, 627 Taylor, Palmer. See Hughes, Boyle, Brown, and Insel, 258 Wolf, C. Roland, Statham, Charles N., McMenamin, Mary G., Thakker, Dhiren R. See Vyas, Levin, Yagi, Ryan, Thomas, Conney, Bend, John R., Boyd, Michael R., and Philpot, Richard M. and Jerina, 182 The Relationship between the Catalytic Activities of Rabbit Pul- Thomas, Paul E. monary Cytochrome P-450 Isozymes and the Lung-Specific Tox- Ryan, Dene E., von Bahr, Christer, Glaumann, Hans, and icity of the Furan Derivative, 4-Ipomeanol, 738 Levin, Wayne. Human Liver Microsomal Epoxide Hydrolase: Woodcock, Elizabeth A., and Johnston, Colin I. Characterization Correlation oflmmunochemical Quantitation with Catalytic Activ- of Adenylate Cyclase-Coupled Alpha2-Adrenergic Receptors in ity, 190 Rat Renal Cortex Using [3H]Yohimbine, 589 See Vya.s, Levin, Yagi, Thakker, Ryan, Conney, and Jerina, 182 W#{252}thrich, Andreas. See Gietzen and Bader, 413 808 AUTHOR INDEX

Y Yoda, Atsunobu and Yoda, Shizuko. Formation of ADP-Sensitive Phosphorylated Yagi, Haruhiko. See Vyas, Levin, Thakker, Ryan, Thomas, Conney, Intermediate in the Electric Eel Na,K-ATPase Preparation, 693 and Jerina, 182 and Yoda, Shizuko. Interaction between Ouabain and the Phos- Yamada, Masakazu. See Suketa, Hasegawa, and Asao, 116 phorylated Intermediate of Na,K-ATPase, 700 Yamakado, Toshiyuki. See Tanaka, Ohmura, and Hidaka, 408 Yoda, Shizuko. See Yoda, 693, 700 CUMULATIVE SUBJECT INDEX’ FOR VOLUMES 21 AND 22

A Adenocarcinoma, colon methotrexate-5-fluorouracil treatment (human), 22, 771 A23187 xenografts (human), 22, 771 effect on cyclic AMP, 22, 310 Adenosine effect on cyclic GMP (guinea pig), 21, 654 A, Acetaldehyde, effect on membrane fluidity, 22, 721 receptor binding heterogeneity (rat, rabbit, guinea pig, calf, hu- Acetaniide, interaction with purified liver microsomal isozymes (rab- man), 22, 250 bit), 21, 701 receptor regulation in brain (guinea pig, bovine), 21, 329 4-Acetoxy-4-androstene-3,17-dione, inhibition of estrogen biosynthesis, antagonism (rat, rabbit, guinea pig, calf, human), 22, 250 21, 173 effect on glucose transport (rat), 22, 614 Acetylcholine effect on insulin receptors (rat), 22, 614 binding, in electroplax membranes (ray), 22, 565 effect on lipid synthesis (rat), 22, 614 channel noise, 22, 565 modulation of insulin sensitivity (rat), 22, 614 interaction with alumina surface, 22, 678 3H-labeled receptor cation regulation (guinea pig, bovine), 21, 329 binding in brain (rat), 22,56 guanine nucleotide regulation (guinea pig, bovine), 21, 329 binding to receptor (ray), 22,63 rescue effects in methotrexate-treated cells (human), 21, 718 muscarinic analogue, interaction with alumina surface, 22, 678 S-Adenosylhomocysteine mcotinic receptor, 21, 351 analogues, carboxymethyltransferase inhibition, 21, 181 mcotinic receptor/channel, binding (ray), 22, 63 bindng to hepatocytes (rat), 21, 108 noise analysis (frog), 22,636 binding to liver plasma membranes (rat), 21, 108 receptor drug specificity (ray), 22,63 S-Adenosyl-L-methionine, inhibitors of biosynthesis (rat), 22, 752 S-Adenosylmethionine, carboxymethyltransferase inhibition, 21, 181 in soleus muscle (rat), 22, 565 ionic channel (frog), 22, 636 Adenovirus, RNA synthesis, 22, 517 Adenylate cyclase ionic channel inactivation (frog), 22, 636 neuromuscular junction (frog), 22, 636 activation by forakolin (human), 21, 680 receptor/channel, pharmacology (ray), 22, 72 by forskolin (rat), 22, 109 sensitivity, 22,565 by forskolin, in lymphoma cells 22, 609 sensitivity (frog), 22, 636 effects of sulihydryl groups (dog), 22, 595 Acetylcholinesterase adipocyte, inhibitors, 21, 336 edrophonium inhibition (ray), 22,63 alpha-adrenergic receptor-coupled, characterization in renal cortex inhibition (ray), 22,63 (rat), 22, 589 inhibition in Torpedo electric organ, 22,63 alpha inhibition, 21, 17 N-Acetylglucosaminidase, platelet secretion (human), 21, 422 N-Acetyltransferase binding in purified platelet membranes (human), 21, 600 cysteine S-conjugate, kidney microsomes (rat), 21, 444 cardiac, thermodependence (rat), 22, 342 compensatory increase, 22, 1 inactivation (hamster), 21, 159 -coupled receptor, anterior pituitary (porcine), 22, 298 multiplicity (hamster), 21, 159 coupling proteins, magnesium regulation (mouse), 22, 267 Aclacinomycin, effect on cytoplasmic RNA in erythroleukemia cells, cultured neuroblastoma, 21, 664 22, 152 dopamine-sensitive (rat), 22, 281 Acridine derivatives energy of activation (rat), 22, 342 antileukemic activity, 22, 486 epinephrine inhibition, 22, 574 DNA binding, 22, 486 genetics (mouse), 22, 267, 274 4’-(9-Acridinylamino)methanesulfon-m-anisidide, monosubstituted de- histamine-mediated stimulation in myocardium (human), 21, 671 rivatives, antileukemic activity, 22, 486 hormonal inhibition, 21, 336 Action potential inhibition, 22, 589 muscle (frog), 21, 637 by alpha2-adrenergic receptors (rat), 21, 648 skeletal muscle (frog, ray), 22, 82 islet cell membrane (rat), 21, 648 retardation, 21, 351 La3 inhibition (mouse), 22, 274 Activation, adenylate cyclase, effects ofsulffiydryl groups (dog), 22, 595 Activity lipid incorporation, 21, 492 magnesium regulation (mouse), 22, 267, 274 antitumor, 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187 membrane lipid effects, 22, 360 3-carbomethoxy rifamycin 5, 21, 394 neuroblastoma cells, opiate inhibition, 21, 483 intrinsic, definition in allozyme hypothesis, 22, 580 monooxygenase-like, of tetrameric hemoglobin (rabbit), 21, 1 opiate inhibition, 22, 1 platelet (human), 22, 574 N-O-Acyltransferase hepatic (hamster), 21, 159 inhibition (human), 21, 609 phenotypes, 849 lymphoma cells (mouse), 22, 204 inactivation (hamster), 21, 159 in receptor coupling, 22, 580 Addiction, opiate, effects on calmodulin activity (rat), 22, 389 receptor coupling (bovine), 21, 52 Adenine nucleosides, effects on RNA synthesis, 22, 517 receptor coupling (mouse), 22, 204 receptor-mediated inhibition (rat), 21, 570

I Boldface numbers indicate appropriate volume; lightface numbers regulation, 22, 580 indicate pagination. renal cortex (rat), 22, 532 809 810 SUBJECT INDEX

Adenylate cyclase-continued molecular associations in aqueous solution, 22, 158 Sc’ inhibition (mouse), 22, 274 Affinity, agonist, prostaglandin E2 receptors in adipocytes (hamster), stimulation by arachidonic acid metabolites, 21, 664 22, 320 system, organization (rat), 22, 342 Affinity states, dopamine receptors (porcine), 22, 298 Adipocyte Aggregation, stimulus-induced, human platelets, 21, 422 adenylate cyclase inhibitors, 21, 336 Agonist antiipolytic agents, 21, 336 acetylcholine receptor, desensitization at neuromuscular junction cyclic AMP accumulation (rat), 22, 109 (frog), 22, 636 effect of forskolin (rat), 22, 109 affinity effect of hypothyroidism (rat), 22, 109 beta-adrenergic receptors (mouse), 22, 204 effect of insulin and adenosine (rat), 22, 614 prostaglandin E2 receptors in adipocytes (hamster), 22, 320 glucose transport (rat), 22, 614 -antagonist interaction, model, 22, 369 insulin receptors (rat), 22, 614 /antagonist two-state binding model, opioid receptor (rat), 22, 349 lipid synthesis (rat), 22, 614 delta, binding (rat), 21, 564 lipolysis (rat), 22, 109 dopamine, comparison (rat), 21, 114 membrane, adrenergic ligand liposolubiity in (rat), 22, 5 dopamine receptor, anterior pituitary (porcine), 22, 290 oxytocin action (rat), 22, 381 edrophonium (ray), 22, 63 oxytocin receptor (rat), 22, 381 histamine, effect on binding and biological response of gastric mu- prostaglandin F42 receptor (hamster), 22, 320 cons! cells (guinea pig), 22, 33 ADP nbosylation, by cholera toxin (mouse), 22, 204 histamine H,, in polymorphonuclear neutrophils (human), 21, 78 Adrenalectomy, effect on hepatic and renal glucose-6-phosphatase ac- histamine H2, in polymorphonuclear neutrophils (human), 21, 78 tivity (rat), 22, 116 -induced desensitization, neuromuscular junction (frog), 22, 636 Adrenergic ligand in vivo regulation (chick), 21, 280 liposolubiity in membranes (rat), 22, 5 mu, binding (rat), 21, 564 n-octanol:water (rat), 22, 5 muscarinic-induced tremor (rat), 21, 594 Adrenergic receptor opiate, potency and efficacy, 21, 483 alpha- platelet alpha2-adrenergic receptor (human), 21, 609 model, 21, 400 quaternary ammonium (rat), 22, 63 role in hepatocyte release of methotrexate (rat), 22, 493 radioligand, binding in neuroblastoma X glioma cells, 21, 17 subtype characterization (rat), 22, 532 retained, effect on alpha2-adrenergic receptors in platelets (human), alpha,- 21, 36 in submandibular gland (rat), 21, 27 striatal dopamine D-1 receptor, characterization (rat), 22, 281 on cloned muscle cell line, coexistence with beta2- (mouse), 22,258 tetramethylammonium (ray), 22, 63 [3H]prazocin (mouse), 22, 258 Albumin, human serum stimulation in parotid cells (rat), 21, 128 binding to warfarin, 21, 100 stimulation of phosphatidylinositol-phosphatidic acid turnover characterization of drug binding area, 21, 387 (rat), 21, 128 interaction with cephalosporins, 21, 92 alpha2- Alcohol, see also Ethanol affinity states, 21, 17 effect on free cholesterol transfer in erythrocytes (human), 21, 694 binding in purified platelet membranes (human), 21, 600 effect on membrane fluidity, 22, 721 binding to adenylate cyclase (rat), 22, 589 dehydrogenase, metabolic compartmentation, 21, 438 conformational requirements, 21, 259 neurochemical effects (rat, mouse), 22, 99 coupling to cyclase, 21, 17 Alkaloid cultured hybrid cells, 21, 17 opiate, binding in brain (rat), 21, 564 “down regulation” in platelets (human), 21, 36 ymca, Ca2-transport ATPase inhibition (human), 22, 413 inhibition of insulin secretion (rat), 21, 648 N-Alkyl analogues, of amantadine, interaction with mcotinic acetylcho- in neuroblastoma X glioma cells, 21, 17 line receptor (ray), 22, 82 in submandibular gland (rat), 21, 27 N-AIkyl compounds, metabolism, 21, 133 platelet (human), 22, 574 Alkyl $-carboline-3-carboxylate binding, brain, thermodynamic platelet membrane and solubilized preparations (human), 21, 609 changes (rat), 22, 335 beta- Alkylation, dopamine receptor (bovine), 21, 44 -adenylate cyclase complex (mouse), 22, 267, 274 Allosteric interactions in brain (rat), 22, 327 agonist affmity (mou.w), 22, 204 Allozyme hypothesis binding in erythrocyt.es (frog, turkey), 21, 5 definition of intrinsic activity, 22, 580 binding system (rat), 22,5 for receptor function, 22, 8O in submandibular gland (rat), 21, 27 Alumina surface, interaction with acetyicholine and ,6-methyl acetyl- interaction with guanine nucleotide binding component (rat), 21, choline, 12, 678 570 Amantadine, stiucture-activity relationships (ray), 22,82 beta2- Ames test [‘251]cyanopindolol (mouse), 22, 258 for mutagemc potency, 21, 187 on cloned muscle cell line, coexistence with alpha,- (mouse), 22, 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187 258 Ametantrone, hepatic microsomal metabolism (rabbit), 22, 471 computer modeling, 22, 532 Amine(s) submandibular gland (rat), 21, 27 aromatic, demethylation, 21, 133 turnover (mouse), 22, 258 biogenic, storage in intact platelets (human), 22,94 Adriamycin lysosomatic, erythrocyte (frog), 22, 619 effect on cytoplasmic RNA in erythroleukemia celLs, 22, 152 pump, substrates (rat), 21, 374 hepatic microsomal metabolism (rabbit), 22, 471 Amino acid, a- and N-methyl, conformational analysis (hydra), 21, 629 SUBJECT INDEX 811

-y-Aminobutyric acid histamine H2 benzodiazepine receptor regulation (mouse), 21, 618 effect on binding and biological response of gastric mucosal cells effect on benzodiazepine binding (rat), 22, 26 (guinea pig), 22, 41 effect on [3Hjdiazepam binding (rat), 22, 26 in polymorphonuclear neutrophils (human), 21, 78 effect on [3H]flumtrazepam binding (rat), 21, 57 nicotinic, binding, 22, 565 -ionophore complex, 21, 320 platelet alpha2-adrenergic receptor (human), 21, 609 mimetics, in brain (rat), 22, 327 radioligand binding in neuroblastoma x glioma cells, 21, 17 modulation (rat), 22, 335 regulatory site, 22, 231 receptor, modulation of cation binding sites (rat), 22, 327 quatemary ammonium (ray), 22, 63 p-Aminoclonidine, 3H-labeled Anthracenedione, inhibition of microsomal oxidative drug metabolism alpha2-adrenergic receptors, 21, 17 (rabbit), 22, 471 binding in purified platelet membranes (human), 21, 600 Anthracycline 5’-Amino-5’-deoxythymidine, inhibition of thymidine kinase, 22, 231 analogues, cytotoxicity, 22, 152 2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, effect on dopa- antitumor effects, 21, 196 mine synthesis (rat), 21, 114 effect on cytoplasmic RNA in erythroleukemia cells, 22, 152 6-Aminolevulinic acid, synthase, effect on organometals (rat), 21, 150 inhibition of microsomal oxidative drug metabolism (rabbit), 22, 471 Aminotransferase, tyrosine, hepatic, effect of pregnenolone-16a-carbo- molecular associations, 22, 158 nitrile (rat), 21, 753 Antiarrhythmic drugs, inhibition of phencyclidine binding (ray), 22, 72 Ammonium Antibody, monoclonal quaternary, agonists and antagonists (ray), 22, 63 distinction of monoamine oxidase A and B, 22, 500 quaternary drugs, interactions in Torpedo electric organ, 22, 63 to cytochrome P-45OLM2 and P-45O,M4, 21, 248 Amphiphiic helices, /1-endorphin, 22, 657 Antibiotics Analgesia binding to acetylcholine receptor (ray), 22, 72 narcotic, 21, 548 inhibition of phencyclidine binding (ray), 22, 72 opiate (rat), 21, 272 Anticonvulsant property Analogue a-substituted -y-butyrolactones (mouse, guinea pig), 22, 438 acetylcholine, interaction with alumina surface, 22, 678 a,-y-substituted y-butyrolactones (mouse, guinea pig), 22, 438 S-adenosylhomocysteine, 21, 181 -y-substituted y-butyrolactones (mouse, guinea pig), 22, 438 binding in liver (rat), 21, 108 Anticonvulsants N-alkyl, of amantadine, interaction with nicotinic acetylcholine re- effect on batrachotoxin binding, 22, 627 ceptor (ray), 22, 82 interaction with benzodiazepine receptors, 21, 320 clonidine, crystallographic and quantum mechanical analysis, 21,400 Antidepressant drugs, inhibition of phencyclidine binding (ray), 22, 72 folic acid, release from hepatocytes (rat), 22, 493 Antidepressants, tricyclic, interaction with phencyclidine (ray), 22, 72 -y-glutamylcysteinylglycine (hydra), 21, 629 Antiestrogen, interaction with muscarinic receptors (rat), 21, 287 L-methionine, substrate and inhibitory properties (rat), 22, 752 Antiherpes, selective agents, 21, 217 methotrexate, 21, 231 Anti-inflammatory drugs norfenfluramine, conformationally defined, 22, 127 metabolism by neutrophils (rat), 21, 688 oxytocin, action in adipocytes (rat), 22, 381 nonsteroidal, structure-activity relationships, 22, 525 phencyclidine (frog), 21, 637 Antileukemic activity, monosubstituted derivatives of 4’-(9-acndinyl- phencyclidine, binding to acetylcholine receptor (ray), 22, 72 amino)methanesulfon-m-anisidide, 22, 486 phenylethylamines, conformationally defined, 22, 127 Antiipolytic agents, adipocyte, 21, 336 synthetic, pumiiotoxin-C, 22, 565 Antimalarial agents, lipophilic chelators, 22, 140 Anesthetic Antimetabolic activity, 5-substituted 2’-deoxycytidines, 21, 217 interaction with benzodiazepine receptors, 21, 320 Antimetabolite, antineoplastic, 21, 224 mechanisms, 22, 133 Antineoplastic agent 1-Aniinonaphthalene-8-sulfonic acid, in study of membrane fluidity, drug synergism, 21, 224 22, 721 microsomal inhibition (rabbit), 22, 471 Anion Antinucleoside, immunoreactivity (mouse), 21, 739 binding sites in brain (rat), 22, 327 Antipsychotic drugs inhibition of skeletal muscle carbonic anhydrase (cat), 22, 211 binding to acetylcholine receptor (ray), 22, 72 recognition sites in brain (rat), 21, 327 inhibition of phencyclidine binding (ray), 22, 72 sulfur trioxide radical, direct detection during oxidation of sulfite, 22, I Antipsychotics, tricyclic, mitochondrial ATPase inhibition (bovine), 21, 732 415 Ansamycins, structure-activity relationships, 21, 394 Antitumor activity Antagonism, uncompetitive, 22, 369 monosubstituted derivatives, 4’-(9-acridinylamino)methanesulfon-m- Antagonist anisidide, 22, 486 adenosine (rat, rabbit, guinea pig, calf, human), 22, 250 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187 -agonist interaction, model, 22, 369 Antitumor effects, of anthracyclines, 21, 196 /agonist two-state binding model, opioid receptor (rat), 22, 349 Antiviral activity, 5-substituted 2’-deoxycytidines, 21, 217 binding, cooperativity studies (rat), 21, 287 Antiviral drugs cahnodulin effect on nicotinic acetylcholine receptor (frog, ray), 22, 82 interaction with Ca2-ca1modulin complex, 22, 403 inhibition of phencycidine binding (ray), 22, 72 phosphorylation modulation, 22, 408 Anxiolytic drug, quantitative structure-activity relationships, 22, 11 dopamine receptor, anterior pituitary (porcine), 22, 290 Aorta, surgical stenosis, effect on cardiac muscarinic receptors (rat), 21, edrophonium (ray), 22, 63 589 histamine H, Apomorphine in polymorphonuclear neutrophils (human), 21, 78 effect on dopamine synthesis (rat), 21, 114 long-acting (rat, guinea pig), 21, 294 ‘H-labeled, dopamine receptor binding (bovine), 21, 44, 52 812 SUBJECT INDEX

9-fl-D-Arabinofuranosyladenine, inhibition of RNA polyadenylation, thermodynamics of binding (rat), 22, 20 22, 517 Benzo[a]pyrene 9-$-D-Arabinofuranosyl-2-fluoroadenine, cytotoxicity, 21, 474 hydroxylation, 21, 248 Arachidonic acid metabolism, 21, 248 metabolism by neutrophils (rat), 21, 688 metabolism (fish), 21, 517 metabolites, stimulation of neuroblastoma adenylate cyclase, 21, 664 metabolism, kinetic determinants (rat), 22, 451 Aroclor 1254 Benzyl hydrodisufflde, inhibition of liver cytochrome P-450 (rat), 21, aryl hydrocarbon hydroxylase induction (rat), 21, 239 464 7-ethoxycoumarin deethylase induction (rat), 21, 239 Binding Aromatase acetylcholine, in electroplax membranes (ray), 22, 565 enzyme catalysis, 21, 173 acridine derivatives, by DNA, 22, 486 inhibition, 21, 173 adenosine A, receptors, species heterogeneity (rat, rabbit, guinea pig, suicide substrates, 21, 173 calf, human), 22, 250 Aromatic compound, molecular association with Adriamycin, 22, 158 S-adenosylhomocysteine, in liver (rat), 21, 108 Arylamide N-hydroxylase, liver, modification (rat), 21, 449 alkyl /?-carboline-3-carboxylate, brain, thermodynamic changes (rat), Aryl hydrocarbon hydroxylase 22, 335 Aroclor induction (rat), 21, 239 antiestrogen (rat), 21, 287 benzo[a]pyrene oxygenation, 21, 248 batrachotoxin, inhibition 22, 627 microsomal activity (mouse), 22, 779 benzodiazepine Arylhydroxamic acid brain, thermodynamic changes (rat), 22, 335 bioactivation (hamster), 21, 159 characterization of peripheral-type sites (rat), 22, 26 suicide inhibitors (hamster), 21, 159 thermodynamics (rat), 22, 20 Aspartate transcarbamylase, inhibition, 21, 224 beta-adrenergic system (rat), 22, 5 Assay, fluorescence, for cellular DNA damage, 22, 145 a-bungarotoxin, in brain (mouse), 22, 554 Astemizole, binding characteristics (rat, guinea pig), 21, 294 carbamylcholine, in electroplax membranes (ray), 22, 565 Astrocytoma cell cation, to glucagon, 22, 105 muscarinic cholinergic receptor (human), 22, 310 delta agonist (rat), 21, 564 phosphodiesterase activity (human), 22, 310 DNA, correlation with anthracycline antitumor potency, 21, 196 ATP [3H]dopamine, caudate nucleus (calf), 22, 281 :L-methiornne S-adenosyltransferase, differences in active-site region dopamine D-1 receptor, characterization (rat), 22, 281 (rat), 22, 752 enthalpy, brain homogenates (rat), 22, 335 platelet secretion (human), 21, 422 enthalpy-driven (rat), 22, 20 ATPase entropy, brain homogenates (rat), 22, 335 (Ca21, cardiac sarcoplasmic reticulum, effect of halothane (bovine), entropy-driven (rat), 22, 20 22, 8 equilibrium, [3H]diazepam, 21, 320 Ca2-transport etorphine, opiate receptors of caudate nucleus (sheep), 22, 648 calmodulin-dependent (human), 22, 413 [3H]etorphine vinblastine inhibition (human), 22, 413 in vitro, 21, 548 heart mitochondrial, fluphenazine inhibition (bovine), 21, 415 receptor in vivo (rat), 21, 272 Atropine, binding in heart (rat), 21, 581 gastric mucosal cells Autonomic receptor, in submandibular gland (rat), 21, 27 effect of histamine agonists (guinea pig), 22, 33 Azapropazone, high-affinity binding sites, 21, 387 effect of histamine H2 antagonists (guinea pig), 22, 41 Aziridinium ions, inhibition of norepinephrine uptake, 21, 380 GTP regulatory protein (bovine), 21, 52 in vitro, characteristics, 21, 294 B in vivo, characteristics (rat, guinea pig), 21, 294 Bacteria, cell wall, penetration by rifamycins, 21, 394 [3H}ketanserin (rat), 21, 301 Barbiturates, interaction with benzodiazepine receptors, 21, 320 kinetics Batrachotoxin, binding to sodium channels, 22, 627 association and dissociation (rat), 21, 57 Bay-region diol epoxide, stereoselective metabolism (rat), 22, 182 human serum albumin, 21, 100 BC3H-1, cloned muscle cell line (mouse), 22, 258 [3H]leucine enkephalin Benzo[a]anthracene, induction of cytochrome P-450 (mouse), 22, 779 effect of morphine (rat), 21, 538 Benzodiazepine in vitro, 21, 548 binding, brain, thermodynamic changes (rat), 22, 335 ligand, 21, 558 binding sites 3H-ligand, effect of heat treatment (bovine), 21, 52 y-aminobutyric acid receptor, modulation (rat), 22, 327 long-acting H1 antagonist (rat, guinea pig), 21, 294 distance geometry analysis, 22, 11 mu agonist (rat), 21, 564 peripheral-type, characterization (rat), 22, 26 muscarinic receptor pharmacophore, 22, 11 aceclidine and its methiodide (rat), 21, 594 receptor in brain (rat), 21, 594 y-aminobutyric acid regulation (mouse), 21, 618 nicotine, in brain (mouse), 22, 554 chloride channel regulation (mouse), 21, 618 nicotinic acetylcholine receptor/channel (ray), 22, 63 heterogeneity (mouse), 21, 618 nonspecific, saxitoxin, 21, 343 in brain (rat), 22, 327 opiate receptor, 21, 483, 492 ion regulation (mouse), 21, 618 in brain (rat), 21, 564 interaction, temperature dependence (rat), 22, 20 opioid receptor, two-state model (rat), 22, 349 interaction with barbiturates, 21, 320 ouabain, to digitalis receptor (rat, guinea pig), 22, 687 membrane (rat), 21, 57 [3H}n-propylapomorphine, in pituitary (porcine), 22, 290, 298 photoaffinity labeling (mouse), 21, 618 protein, human serum albumin, 21, 100 SUBJECT INDEX 813

quinucidinyl benzilate, in brain (mouse), 22, 554 properties, 21, 217 radioligand (E)-5-(2-Bromovinyl)-2’-deoxyuridine computer modeling, 21, 5 differential antiviral activity, 21, 432 in submandibular gland (rat), 21, 27 phosphorylation, 21, 432 receptor a-Bungarotoxin $-endorphin models, 22, 657 binding in brain (mouse), 22, 554 guanine nucleotide regulation (hamster), 22, 320 receptor, binding in brain (mouse), 22, 554 monovalent cations (hamster), 22, 320 y-Butyrolactone site alkyl-substituted, structure-activity relationships (mouse, guinea anion, in brain (rat), 22, 327 pig), 22, 444 benzodiazepine, distance geometry analysis, 22, 11 a-substituted, anticonvulsant properties (mouse, guinea pig), 22, 438 benzodiazepine, in brain (rat), 22, 327 a,y-substituted, anticonvulsant properties (mouse, guinea pig), 22, cardiac, effects of guanine nucleotides (rat), 21, 581 438 cation, y-aminobutyric acid modulation (rat), 22, 327 $-alkyl-substituted, eleptogenic properties (mouse, guinea pig), 22, characterization, 21, 387 431 high-affinity, azapropazone, 21, 387 -y-substituted, anticonvulsant properties (mouse, guinea pig), 22, 438 high-affinity, warfarin, 21,387 unsubstituted, eleptogenic properties (mouse, guinea pig), 22, 431 insulin, in erythrocytes (frog), 22, 619 opiates, 21, 266 picrotoxin, in brain (rat), 22, 327 C saxitoxin, structure, 21, 343 Ca2, see also Calcium sodium channels in nerve membranes, 21, 343 -ATPase, cardiac sarcoplasmic reticulum, effect of halothane (bo- spiperone, in brain (rat), 22, 243 vine), 22, 8 [3H]spiroperidol -calmodulin-dependent phosphorylation, 22, 408 caudate nucleus (calf), 22, 281 -calmodulin complex, interaction with calmodulin antagonists, 22, pituitary (porcine), 22, 290, 298 403 substance P derivative, to mesencephalic cells (mouse), 22, 48 -H exchange diffusion (mouse), 22, 715 toxin molecules, exchange of tritium, 21, 343 ionophore two-site model (cat), 22, 304 effect on cyclic AMP, 22, 310 zinc, to glucagon, 22, 105 hypoglycemic sulfonylureas (mouse), 22, 715 Biogenic amines, storage in intact platelets (human), 22, 94 phospholipid-dependent phosphorylation, 22, 408 Biosynthesis -transport ATPase, calmodulin-dependent (human), 22, 413 estrogen, inhibition, 21, 173 Cadmium-sensitive hepatic cytochrome P-450 (rat), 22, 795 prostaglandin, N-alkylation during, 21, 133 Calcium, see also Ca2 Bisbenzamide, assay for cellular DNA damage, 22, 145 effect of halothane at low concentrations (bovine), 22, 8 1,4-Bis(2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione platelet secretion (human), 21, 422 diacetate, inhibition of microsomal oxidative drug metabolism stimulus-induced mobilization in human platelets, 21, 422 (rabbit), 22, 471 transport Bladder, urinary, water flow (toad), 21, 142 in excitable cells (mouse), 22, 715 Blood platelets, storage of biogenic amines (human), 22, 94 in isolated secretory granules (mouse), 22, 715 Blot hybridization uptake DNA (mouse), 22, 779 glutamate-stimulated (rat, mouse), 22, 99 mRNA (mouse), 22, 779 potassium-stimulated (rat, mouse), 22, 99 Brain synaptosomal (rat, mouse), 22, 99 [3Hjacetylcholine binding sites (rat), 22, 56 Calmodulin adenosine A, receptor binding, species heterogeneity (rat, rabbit, antagonist guinea pig, calf, human), 22, 250 effect on human platelets, 21, 422 adenylate cyclase, effects of sulhydryl groups (dog), 22, 595 interaction with Ca2-calmodulin complex, 22, 403 alkyl fl-carboline-3-carboxylate binding (rat), 22, 335 phosphorylation modulation, 22, 408 y-aminobutyric acid receptors (rat), 22, 327 -Ca2 complex, interaction with calmodulin antagonists, 22, 403 ATP concentration, effect of morphine (rat), 22, 706 effects of morphine treatment (rat), 22, 389 benzodiazepine -dependent Ca2-transport ATPase (human), 22, 413 binding (rat), 22, 335 human platelet, effect of trifluoperazine, 21, 422 binding, characterization of peripheral-type sites (rat), 22, 26 inhibition (bovine), 21, 86 receptors (mouse), 21, 618 inhibitors, in C6 glioma cells, 22, 395 receptors (rat), 22, 327 vinblastine binding (human), 22, 413 digitalis receptor, inhibition of ouabain binding (rat), 22, 687 Carbachol effects of morphine treatment on calmodulin activity (rat), 22, 389 cyclic GMP stimulation (guinea pig), 21, 654 embryonic, muscarinic receptors (chick), 21, 280 effect on cultured thyroid cells (porcine), 21, 66, 73 [3H]ketanserin distribution (rat), 21, 301 fatty acid hydroperoxides, cyclic GMP (guinea pig), 21, 654 membrane, opiate binding (rat), 21, 564 -induced desensitization, cultured thyroid cells (porcine), 21, 73 nicotinic cholinergic receptors (rat), 22, 56 phospholipase A2 stimulation (guinea pig), 21, 654 particulate fraction, [‘H]leucine enkephalin binding (rat), 21, 538 Carbamazepine, effect on batrachotoxin binding, 22, 627 protein synthesis inhibition by morphine (rat), 22, 706 Carbamoylation, in nitrosourea cytotoxicity (rat), 21, 729 serotonin receptors, characterization (rat), 22, 243 Carbamylcholine binding spiperone binding (rat), 22, 243 in electroplax membranes (ray), 22, 565 5-Bromo-2’-deoxycytidine, antiherpes activity, 21, 217 in heart (rat), 21, 581 (E)-5-(2-Bromovinyl)-2’-deoxycytidine, antiviral and antimetabolic Carbomethoxy, stereospecificity at position 10, 21, 196 814 SUBJECT INDEX

3-Carbomethoxy rifamycin 5, molecular structure by ‘H NMR and X- lethality rays, 21, 394 5-fluorouracil (human), 21, 468 Carbon-centered free radical (rat), 22, 239 5-fluorouridine (human), 21, 468 Carbon dioxide, hydration activity of skeletal muscle (cat), 22, 211 leukemia, hypoxic, synergistic toxicity of misomdazole and sulfido- Carbonic anhydrase, skeletal muscle, carbon dioxide hydration activity cyclophosphamide (mouse), 22, 175 (cat), 22, 211 lymphoblast, deoxyuridine metabolism (human), 22, 166 Carboxymethyltransferase, synaptosomal, inhibition (calf, rat), 21, 181 mesencephalic, substance P derivative binding (mouse), 22, 48 Carcinogen, chemical, phenacetin, 22, 479 methotrexate-treated, 21, 204 Carcinogenesis, role of bay-region diol epoxide (rat), 22, 182 rescue effects of folinic acid and glycine, adenosine, and thymidine Carcinogenicity, polycyclic aromatic hydrocarbons, 22, 459 (human), 21, 718 Carcinoma morphological transformation (mouse), 21, 739 colon, cultured cells (human), 21, 468 muscle, cloned, BC3H-l (mouse), 22, 258 selective cytotoxicity of haloethylnitrosoureas (rat), 21, 729 neuroblastoma Walker 256 (rat), 21, 729 serotonin uptake, 21, 362 Cardiotoxicity, anthracycline antineoplastic agents, 22, 471 tyrosine hydroxylase induction (mouse), 22, 421 Carminomycin, effect on cytoplasmic RNA in erythroleukemia cells, neuroblastoma N18TG2 22, 152 opiate inhibition, 21, 483 Catalysis, aromatase enzyme, 21, 173 potentiation of opiate action, 21, 492 Catalytic activity neuroblastoma x glioma hybrid, adenylate cyclase activity, 22, 360 liver microsomal epoxide hydrolase (human), 22, 190 neuroblastoma x glioma NG1O8-15 hybrid pulmonary cytochrome P-450 isozymes (rabbit), 22, 738 opiate inhibition, 21, 483 Catecholamine opiate receptor activity, 22, 1 effect on adenylate cyclase in myocardium (human), 21, 671 neuronal, culture (mouse), 22, 48 effect on binding in platelets (human), 21, 609 parotid, phosphatidylinositol-phosphatidic acid turnover (rat), 21, effect on binding in purified platelet membranes (human), 21, 600 128 effect on ion fluxes in erythrocytes (turkey), 21, 503 pheochromocytoma -induced release of methotrexate from hepatocytes (rat), 22, 493 norepinephrine uptake, 21, 368 receptor, binding in erythrocytes (frog, turkey), 21, 5 serotonin uptake, 21, 368 Cation proliferation (human), 22, 547 binding, glucagon, 22, 105 promyelocytic leukemia HL-60 (human), 22, 547 binding sites, y-aminobutyric acid modulation (rat), 22, 327 5180 AT/3000, dihydrofolate reductase (mouse), 21, 231 fluxes, in erythrocytes (turkey), 21, 503 549 lymphoma, adenylate cyclase phenotypes (mouse), 22, 204 monovalent thyroid effect on binding in platelets (human), 21, 609 culture (porcine), 21, 66, 73 effect on binding in purified platelet membranes (human), 21, 600 muscarinic cholinergic receptors on (porcine), 21, 66, 73 effect on prostaglandin E2 receptors in adipocytes (hamster), 22, Central nervous system 320 depressant drugs, 21, 320 receptor regulation (guinea pig, bovine), 21, 329 receptors, in vitro, 21, 315 recognition sites in brain (rat), 22, 327 substance P binding (mouse), 22, 48 Caudate membrane, 3H-ligand binding sites (bovine), 21, 44, 52 Cephalosporin, interaction with human serum albumin, 21, 92 Caudate nucleus, opiate receptors, etorphine binding (sheep), 22, 648 Cerebroside sulfate, acidic lipids, 21, 492 Cell CF 25-397, see 9, l0-Didehydro-6-methyl-3$- (2-pyridylthiomethyl)- antinucleoside immunoreactivity (mouse), 21, 739 ergoline astrocytoma Channel noise, acetylcholine, 22, 565 muscarinic cholinergic receptor (human), 22, 310 Chelator, lipophiic, antimalarial activity, 22, 140 phosphodiesterase activity (human), 22, 310 CHEMLAB, triazene mutagenicity analysis, 21, 187 carcinoma Chemotherapy, drug design, 22, 231 in culture (human), 21, 468 Chioramphenicol, cytochrome P-450 inactivation (rat), 21, 166 resistance to bifunctional nitrogen mustards (rat), 21, 729 Chloride channel, benzodiazepine receptor regulation (mouse), 21, 618 selective toxicity of haloethylnitrosoureas (rat), 21, 729 N-2’-Chloroethyl-N-ethyl-2-methylbenzylamine, chemical transforma- culture, L1210 leukemia, 22, 486 tions in solution, 21, 380 cycle, effect of methotrexate, 21, 204 N-2’-Chloroethyl-2-methylbenzylamine, inhibition of norepinephrine cytochrome P-450, effect of organometals (rat), 21, 150 uptake, 21, 380 differentiation (human), 22, 547 1-Chloro-2,2,2-trifluoroethyl radical, binding to phospholipids (human, DNA rabbit), 21, 710 fluorescence assay for damage, 22, 145 Chlorpromazine, ring sulfoxidation, 21, 409 strand separation (mouse), 21, 739 Cholera toxin erythroleukemia, RNA transport, 22, 152 ADP ribosylation (mouse), 22, 204 excitable, calcium transport (mouse), 22, 715 effect on cardiac adenylate cyclase activity (rat), 22, 342 gastric mucosa, interaction with histamine (guinea pig), 22, 33, 41 Cholesterol, free, transfer into erythrocytes (human), 21, 694 glioma C6 Cholic acid, sodium salt, effect on opiate binding (rat), 21, 564 calmodulin inhibitors, 22, 395 Cholinergic receptor glycogen phosphorylase conversion B to A, 22, 395 muscarinic (mouse), 22, 554 HeLa, 9-$-D-arabinofuranosyl-2-fluoroadenine inhibition (human), nicotinic (mouse), 22, 554 21, 474 Chromaffin granules, calcium transport (mouse), 22, 715 KB Chromatin, thymus dihydrofolate reduct.ase (human), 21, 231 formaldehyde cross-linking (calf), 22, 121 methotrexate-resistant (human), 21, 231, 248 methylmercury complexes (calf), 22, 121 SUBJECT INDEX 815

Chromatography neuroblastoma cells column, pulmonary cytochrome P-450 (rabbit), 22, 221 adenylate cyclase, 21, 664 high-pressure liquid, benzo[a]pyrene metabolism, 21, 248 serotonin uptake, 21, 362 Chromosome neuronal cells (mouse), 22, 48 markers, in nitrosourea cytotoxicity (rat), 21, 729 pheochromocytoma cells modal number (rat), 21, 729 norepinephrine uptake, 21, 368 Chrysene 1,2-dihydriols, stereoselective metabolism (rat), 22, 182 serotonin uptake, 21, 368 Circular dichroism, glucagon, 22, 105 primary, mesencephalic cells (mouse), 22, 48 Clomiphene, interaction with muscarinic receptors (rat), 21, 287 Current, end-plate Clone amplitude, 22, 565 cDNA, for P,-450 (mouse), 22, 779 decay, 22, 565 muscle cell line, BC3H-1 (mouse), 22, 258 Curve-fitting technique, computerized, discrimination of opiate recep- neuroblastoma variants, characterization, 22, 196 tor binding sites, 21, 266 Clonidine, pharmacology, 21, 400 Cyanopindolol, 3H-labeled, beta2-adrenergic receptor (mouse), 22, 258 Cocaine metabolite, hepatotoxicity (rat, hamster), 21, 458 Cyclic AMP Colchicine, effect on urinary bladder (toad), 21, 142 accumulation in adipocytes (rat), 22, 109 Colon accumulation in lymphoma cells, 22, 609 adenocarcinoma accumulation in van deferens (mouse), 22, 602 methotrexate-5-fluorouracil treatment (human), 22, 771 degradation in astrocytoma cells (human), 22, 310 xenografts (human), 22, 771 enhancement of tyrosine hydroxylase induction (mouse), 22, 421 carcinoma, cultured cells (human), 21, 468 forskolin activation (rat), 22, 109 xenografts, selectivity (human), 22, 7711 generation in pancreatic islets (rat), 21, 648 Complex in promyelocytic leukemia cells (human), 22, 547 cephalosporin-human serum albumin, 21,92 levels in cultured thyroid cells (porcine), 21, 66 metabolic-intermediate, cytochrome P-450, from isosafrole (rat), 21, myocardial (human), 21, 671 527 neuroblastoma cell (mouse), 22, 421 Computer modeling platelet levels (human), 21, 680 adrenergic receptors, 22, 532 inhibition by forskolin, 21, 680 for radioligand binding data, 21, 5 polymorphonuclear neutrophils (human), 21, 78 Computerized curve-fitting technique, discrimination ofopiate receptor protein kinase (rat), 21, 121 binding sites, 21, 266 receptors, in erythrocytes (turkey), 21, 503 Concanavalin A, regulation of insulin receptors in erythrocytes (frog), Cyclic GMP, carbachol stimulatory effect (guinea pig), 21, 654 22, 619 Cyclohexyladenosine, 3H-labeled, binding to adenosine A, receptors in Conformation brain (guinea pig, bovine), 21, 329 -energy calculations, 22, 667 Cyclooxygenase, metabolism of arachidonic acid by neutrophils (rat), interconvertible, benzodiazepine receptor (rat), 21, 57 21, 688 sodium channel, 21,343 Cysteine, S-conjugate N-acetyltransferase, kidney microsomes (rat), Conformational analysis 21,444 a- and N-methyl amino acids (hydra), 21,629 Cytochrome l-(Lphenyl)-3,3-dialkyltriazenes, 21, 187 b5, substrate interaction (rabbit), 21, 701 Conformational change, glucagon, 22, 105 P-450 Conformational model, two-state, for phenylethanolamine N-methyl- cardiac microsomes (fish), 21, 517 transferase, 22, 127 cellular, effect of organometals (rat), 21, 150 Conformational preference, phenylethanolamine N-methyltransferase content in neonatal skin (rat), 21, 239 substrates, 22, 127 effects of cadmium (rat), 22, 795 Conformational requirements, alpha2-adrenergic receptors, 21, 259 electrophoresis, 22, 787 Conformer, active/inactive, 22, 667 ‘H Fourier transform studies (rabbit), 21, 701 Constant, high metal binding, oxine, 22, 140 H2O2 generation by hydroxylamines (rat), 22, 465 Cooperativity hepatic, alkyl halide metabolism (rat), 22, 745 antiestrogen with muscarinic receptors (rat), 21, 287 hepatic, cadmium-sensitive (rat), 22, 795 lipid transition, 22, 133 hepatic, immunochemistry (rat), 21, 753 Co-oxidation, prostaglandin synthetase, 21, 133 hepatic, inactivation (rat), 21, 166 Correlation, dopamine-sensitive adenylate cyclase/[’H]dopamine bind- hepatic, induction with pregnenolone-16a-carbonitrile (rat), 21, ing, 22, 281 753 Cortex, cerebral, synaptosomal membranes (rat), 21, 57 hepatic, neonatal imprinting and (rat), 21, 744 Coupling hepatic, neonatally imprinted forms (rat), 21, 744 collision, bidirectional, to adenylate cyclase, 22, 580 hepatic, opposing effects of N-hydroxyamphetamine and N-hy- factor, definition, 22, 580 droxyphentermine (rat), 22, 465 receptors to adenylate cyclase, 22, 580 hepatic, reconstituted (rabbit), 22, 235 Cross-reaction minimalization, opiate alkaloid and peptide, by man- hepatic, reduction of gentian violet (rat), 22, 239 ganese (rat), 21, 564 hepatic, sex-dependent forms (rat), 21, 744 Crystallographic analysis, clonidine, 21, 400 hepatic, stereoselective metabolism (rat), 22, 182 Culture hepatic, turnover (rat), 21, 744 carcinoma cells (human), 21, 468 immunochemical studies (rat), 21, 744 L1210 cells, cytotoxicity of 5-fluoro-5’-O-nitro-2’-deoxyuridine, 22, induction, genetic differences (mouse), 22, 779 760 inhibition by benzyl hydrodisulfide (rat), 21, 464 L1210 leukemia cells, 22, 486 metabolic-intermediate complexes from isosafrole (rat), 21, 527 Lymphoblasts, deoxyuridine metabolism (human), 22, 166 microsomal, of skin, dermis, and epidermis (rat), 21, 239 816 SUBJECT INDEX

Cytochrome-continued dine, metabolic inhibition (mouse), 22, 766 P-450-continued Diarachidonyl diglyceride, formation by neutrophils (rat), 21, 688 multiple forms (rat), 22, 795 Diazepam, ‘H-labeled, equilibrium binding, 21, 320 NADPH reductase, hepatic microsomal (rabbit), 22, 471 9,10-Didehydro-6-methyl-3$-(2-pyridylthiomethyl)ergoline, effect on N-oxidation of phentermine (rabbit), 22, 235 dopamine synthesis (rat), 21, 114 pulmonary, isozymes (rabbit), 22, 738 fl-Diethylaminoethyl-2,2-diphenylpentanoate, translocation of estrogen pulmonary, 3-methylcholanthrene induction (rabbit), 22, 221 receptor (rat), 21, 533 pulmonary, multiple forms (rabbit), 22, 221 Diethylphenylxanthine, ‘H-labeled, binding to adenosine A, receptors pulmonary, role in toxicity of 4-ipomeanol (rabbit), 22, 738 in brain (guinea pig, bovine), 21, 329 pulmonary, spectral and electrophoretic properties (rabbit), 22, Differentiation, cellular (human), 22, 547 221 Digitalis receptor, light-enhanced inhibition ofbinding (rat, guinea pig), radical formation (rat), 22, 239 22, 687 reductive metabolism of halothane (human, rabbit), 21, 710 Diglyceride, diarachidonyl, formation by neutrophuls (rat), 21, 688 sex differentiation (rat), 22, 795 Dihydriol epoxide, formation in liver (rat), 22, 451 subpopulations, induction by isosafrole (rat), 21, 527 Dihydroalprenolol, 3H-labeled subpopulations, induction by /3-naphthoflavone (rat), 21, 527 adipocyte membranes (rat), 22, 5 subpopulations, induction by phenobarbit.al (rat), 21, 527 binding in erythrocytes (frog, turkey), 21, 5 substrate interaction (rabbit), 21, 701 Dihydrofolate reductase P-450,,,, 3-methylcholanthrene induction (rabbit), 22, 221 effect of methotrexate (human), 21, 478 P-45OLM2, monoclonal antibodies to, 21, 248 in human KB cells, 21, 231 P-45OLM4, monoclonal antibodies to, 21, 248 mouse cell lines, inhibition by antilolate BW3O1U, 22, 766 P,-450 Dihydromorphine, ‘H-labeled, binding in brain (rat), 22, 349 messenger RNA (mouse), 22, 779 Dihydroxyaminotetralins, effect on dopamine receptor binding (rat), protein (mouse), 22, 779 22, 281 Cytometry, flow, deoxyuridine treatment in lymphoblasts (human), 22, 3,4-Dihydroxyphenylamino-2-jmidazoline, effect on dopamine synthe- 166 sis (rat), 21, 114 Cytoplasm, RNA, effect of anthracyclines, 22, 152 5,6-Dihydroxytryptamine, cytotoxic effect, 21, 362, 368 Cytotoxicity, see also Toxicity 5,7-Dihydroxytryptamine, cytotoxic effect, 21, 362, 368 anthracycline analogues, 22, 152 Dimer, enkephalin, affinity and selectivity for delta opiate receptor, 21, deoxyuridine (human), 22, 166 558 5-fluorodeoxyuridine, 21, 211 Dimethylaniline N-oxidase, quantitation, 22, 787 in gastrointestinal tumor (human), 21, 723 Diol epoxide, bay-region, stereoselective metabolism (rat), 22, 182 5-fluoro-5’-O-nitro-2’-deoxyuridine, in L1210 cultures, 22, 760 Dipalmitoylphosphatidylcholine methotrexate, 21, 204 model membrane, fluidity, 22, 721 methotrexate (human), 21, 718 thermotropic properties, effects of ethanol, 22, 133 in gastrointestinal tumor, 21, 723 transitions, 22, 133 misonidazole (mouse), 22, 175 Diphenylhydantoin, effect on batrachotoxin binding, 22, 627 selective, haloethylnitrosoureas in carcinoma (rat), 21, 729 Diprenorphine, 3H-labeled, binding in intact cells, 22, 1 5-substituted 2’-deoxycytidines, 21, 217 Distance geometry, benzodiazepine binding site, 22, 11 Diterpene, forskolin, effect on platelets (human), 21, 680 D DNA Daunomycin, effect on cytoplasmic RNA in erythroleukemia cells, 22, adduct, hepatic (rat), 22, 451 152 binding Deactivating system, basal, postulated, 22, 580 correlation with anthracycline antitumor potency, 21, 196 Decomposition, superoxide spin-trapped adducts, 21, 262 correlation with nucleic acid synthesis inhibition, 21, 196 Dehydrogenase, alcohol, metabolic compartmentation, 21,438 complementary, cloned, for P,-450 (mouse), 22, 779 Dehydrogenase, NADH, hepatic microsomal (rabbit), 22, 471 cross-linking, in hypoxic leukemia cells (mouse), 22, 175 De novo constants, correlations between, 22, 725 damage Depressant drugs, interaction with benzodiazepine receptors, 21, 320 fluorescence assay, 22, 145 3’-Deoxyadenosine, effect on RNA synthesis, 22, 517 phenacetin metabolite-induced, 22, 479 2’-Deoxycytidines, 5-substituted, antiviral, antimetabolic, and cytotoxic -dependent RNA polymerase, inhibition by rifamycins, 21, 394 activities, 21, 217 -derived bases, molecular associations with Adriamycin, 22, 158 Deoxyuridine drug binding, acridine derivatives, 22, 486 cytotoxicity (human), 22, 166 5-fluorouracil incorporation, 21, 211 phosphates, cytosol, 21, 224 fragmentation and repair, 21, 211 4-Demethoxydaunomycin, effect on cytoplasmic RNA in erythroleu- inhibition, methotrexate (human), 21, 718 kemia cells, 22, 152 nucleotide levels, 21, 211 Desensitization polymerase, inhibition (human), 21, 474 cultured thyroid cells (porcine), 21, 73 strand separation (mouse), 21, 739 neuromuscular junction (frog), 22, 636 synthesis, in cultured colon carcinoma cells (human), 21, 468 Desmethylimipramine uracil incorporation, 21, 211 inhibition of norepinephrine uptake, 21, 368 Dopamine inhibition of serotonin uptake, 21, 362, 368 agonists (rat), 22, 281 Dexamethasone, induction of hepatic cytochrome P-450 (rat), 21, 753 comparison, 21, 114 Dexetimide, inhibition of binding in heart (rat), 21, 581 3H-labeled Dialysis, equilibrium, cephalosporin-human serum albumin complexes, binding to caudate nucleus (calf), 22, 281 21, 92 receptor binding (bovine), 21, 44, 52 2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-djpyrimi- receptor SUBJECT INDEX 817

affinity states (porcine), 22, 298 model peptides, 22, 657 anterior pituitary gland (porcine), 22, 290, 298 structural characteristics, 22, 657 auto, y-aminobutyric acid technique (rat), 21, 114 End-plate current auto-, synaptosomal tyrosine hydroxylation (rat), 21, 114 amplitude, 22, 565 D-1, characterization (rat), 22, 281 blockade, 21, 351 D-1, model (rat), 22, 281 decay, 22, 565 D-2 (bovine), 21, 44, 52 effect of N-alkyl analogues (ray), 22, 82 D-3 (bovine), 21, 44, 52 neuromuscular (frog), 22, 636 subtypes (bovine), 21, 44, 52 time constant (frog), 21, 637 two affinity states (porcine), 22, 290 Energy-conformation calculations, 22, 667 -sensitive adenylate cyclase Enkephalin effects of sulihydryl groups (dog), 22, 595 (D-A1a2, D-Leu5)-, binding sites, 21, 266 striatal (rat), 22, 281 dimeric, affinity and selectivity for delta opiate receptor, 21, 558 -sensitive adenylate cyclase complex, role of sulfhydryl groups in effects in opiate addiction (rat), 22, 389 coupling (dog), 22, 595 [3H}leucine synthesis, autoreceptor control (rat), 21, 114 binding, effect of morphine (rat), 21, 538 Dose-response curves, modification, 22, 369 binding in vitro, 21, 548 “Down-regulation,” platelet alpha2-adrenergic receptors (human), 21, receptor, and morphine receptor, allosteric coupling in vitro, 21, 548 36 Enthalpy Doxorubicin, see Adriamycin binding, brain homogenates (rat), 22, 335 Drug(s) -driven binding process (rat), 22, 20 anxiolytic, quantitative structure-activity relationships, 22, 11 Entropy binding area, characterization in human serum albumin, 21, 387 binding, brain homogenates (rat), 22, 335 design, chemotherapy, 22, 231 -driven binding process (rat), 22, 20 enzyme regulatory site-directed, 22, 231 Environmental pollutants, effect on heme metabolism (rat), 21, 150 intercalating, cellular effects (mouse), 21, 739 Enzyme metabolism aromatase, catalysis, 21, 173 in neonatal epidermis (rat), 21, 239 cardiac microsomal (fish), 21, 517 sexual differences (rat), 21, 744 induction nonsteroidal anti-inflammatory, structure-activity relationships, 22, phenobarbital (rat), 21, 511 525 trans-stilbene oxide (rat), 21, 511 opiate, inhibition of phencycidine binding (ray), 22, 72 liver, stereoselective metabolism of polycycic aromatic hydrocarbon quatemary ammonium, interactions in Torpedo electric organ, 22, substrates (rat), 22, 182 63 microsomal, comparison, 22, 787 resistance, in carcinoma cell line (rat), 21, 729 modulation, in KB cells (human), 21, 478 dThd kinase, virus-coded, 21, 432 regulatory site-directed drugs, 22, 231 dTMP kinase, virus-coded, 21, 432 secretion dUMP, intracellular, effect of 5-fluorodeoxyuridine, 21, 211 in parotid gland (rat), 21, 121 dUTP, intracellular, effect of 5-fluorodeoxyuridine, 21, 211 regulation (rat), 21, 121 Dynorphin binding sites, 21,266 Epidermis, neonatal, drug metabolism (rat), 21, 239 Epinephrine E inhibition of platelet adenylate cyclase (human), 22, 574 Edrophomum 3H-labeled, alpha2-adrenergic receptors, 21, 17 inhibition of acetylcholinesterase (ray), 22, 63 pressure activity, 22, 725 agonist and antagonist activity (ray), 22, 63 Epoxide hydratase, nuclear envelope induction (rat), 21, 511 Effector blockade, modification of dose-response curves, 22, 369 Epoxide hydrolase Electron spin resonance, microsomal reduction of gentian violet (rat), activity in neonatal skin (rat), 21, 239 22, 239 catalytic activity (human), 22, 190 Electrophoresis liver microsomal (human), 22, 190 coupled with immunochemical staining, 22, 787 Epoxide stability, polycyclic aromatic hydrocarbons, 22, 459 cytochrome P-450, 22, 787 Equilibrium pulmonary cytochrome P-450 (rabbit), 22, 221 dialysis, cephalosporin-human serum albumin complexes, 21, 92 Eleptogenic property fluorescence, warfarin binding, 21, 100 $-alkyl-substituted -y-butyrolactones (mouse, guinea pig), 22, 431 Erythrocytes unsubstituted y-butyrolactones (mouse, guinea pig), 22, 431 cation fluxes (turkey), 21, 503 Embryo, brain, muscarinic receptors (chick), 21, 280 cyclic AMP receptors (turkey), 21, 503 Enantiomer free cholesterol transfer (human), 21, 694 aceclidine, binding in brain (rat), 21, 594 insulin receptors, regulation by insulin and concanavalin A (frog), 22, methotrimeprazine, differential stereoselectivity, 21, 315 619 Endocrine regulation of cadmium-sensitive hepatic cytochrome P-450 membrane, radioligand binding (frog, turkey), 21, 5 (rat), 22, 795 Erythroleukemia cell, cytoplasmic RNA, effect of anthracyclines, 22, Endoplasmic reticulum 152 rough, epoxide hydratase activity (rat), 21, 511 Erythrosine, effect on ouabain binding to digitalis receptor (rat, guinea smooth, epoxide hydratase activity (rat), 21, 511 pig), 22, 687 Endorphin, effects in opiate addiction (rat), 22, 389 Estrogen fl-Endorphin biosynthesis, inhibition, 21, 173 amphiphiic a- or ir-helix, 22, 657 receptor, translocation by SKF 525-A (rat). 21, 533 interaction with calmodulin (bovine), 21, 86 Estrogenic action, SKF 525-A (rat), 21, 533 818 SUBJECT INDEX

Ethanol, see also Alcohol Fluoxetine effect on dipalmitoylphosphatidylcholine, 22, 133 inhibition of norepinephrine uptake, 21, 368 effect on free cholesterol transfer in erythrocytes (human), 21, 694 inhibition of serotonin uptake, 21, 362, 368 in vitro effects (rat, mouse), 22, 99 Fluxes lipid effects, 22, 133 potassium, in erythrocytes (turkey), 21, 503 lipid solubiity, 22, 133 sodium, in erythrocytes (turkey), 21, 503 metabolism in perfused liver (rat), 21, 438 Folic acid analogue, release from hepatocytes (rat), 22, 493 7-Ethoxycoumarin deethylase Folinic acid, rescue effects in methotrexate-treated cells (human), 21, Aroclor induction (rat), 21, 239 718 cytochrome P-450 inhibition, 21, 248 Formaldehyde, cross-linking, methylmercury complexes in thymus Ethoxyresorufin O-deethylase, activity in cardiac microsomes (fish), (calf), 22, 121 21, 517 Forskolin Ethylketocyclazocine binding sites, 21, 266 activation of adenylate cyclase in lymphoma cells, 22, 609 N-Ethylmaleimide activation of cyclic AMP (rat), 22, 109 adenylate cyclase inhibition (dog), 22, 595 activation of lipolysis (rat), 22, 109 effect on pituitary dopamine receptors (porcine), 22, 298 effect on adenylate cyclase (rat), 22, 109 receptor coupling (rat), 21, 570 effect on platelets (human), 21, 680 5-Ethynyl-2’-deoxycytidine, antiherpes activity, 21, 217 Fourier transform, ‘H, NMR studies on cytochrome P-450 (rabbit), 21, Etorphine 701 binding to opiate receptors of caudate nucleus (sheep), 22, 648 Free-Wilsoman group contributions, theorem, 22, 725 “H-labeled Furan derivative, lung toxicity (rabbit), 22, 738 binding, 21, 548 G receptor binding in vivo (rat), 21, 272 Gastric mucosa cells, interaction with histamine (guinea pig), 22, 33, 41 F Gastrointestinal tumor Fatty acids cytotoxicity of 5-fluorodeoxyuridine and methotrexate (human), 21, effects on adenylate cyclase, 22, 360 723 effects on receptors, 22, 360 thymidylate synthetase levels in cells (human), 21, 723 hydroperoxides, soluble guanylate cyclase activation (guinea pig), 21, Genetic complementation, somatic mutants (mouse), 22, 204 654 Genetic mutation, single-gene (mouse), 22, 204 Flavin-containing monooxygenase, estimation, 22, 787 Genetics, adenylate cyclase (mouse), 22, 267, 274 Flow cytometry Gentian violet, microsomal reduction (rat), 22, 239 deoxyuridine treatment in lymphoblasts (human), 22, 166 Glioma cell, C6 methotrexate-treated cells, 21, 204 calmodulin inhibitors, 22, 395 Fluidity, model membrane, 22, 721 glycogen phosphorylase conversion, B to A, 22, 395 Flunitrazepam Glucagon “H-labeled, kinetics of binding (rat), 21, 57 cation binding, 22, 105 nonlinear van’t Hoff plot (rat), 22, 20 circular dichroism, 22, 105 Fluorescence conformational change, 22, 105 enhancement assay for cellular DNA damage, 22, 145 effect on cardiac adenylate cyclase activity (rat), 22, 342 equilibrium, warfarin binding, 21, 100 fluorescence, 22, 105 glucagon, 22, 105 zinc binding, 22, 105 quenching, DNA drug binding, 22, 486 Glucocorticoids, tyrosine hydroxylase induction (mouse), 22, 421 stopped-flow, 21, 100 Glucose terbium, 22, 105 oxidation, oxytocin stimulation (rat), 22, 381 Fluoride, effect on hepatic and renal glucose-6-phosphatase activity transport (rat), 22, 116 adipocyte, effects of adenosine (rat), 22, 614 Fluorimetry effects of oxytocin (rat), 22, 381 binding study, 21, 100 Glucose-6-phosphatase binding of warfarin to human serum albumin, 21, 100 activity in kidney (rat), 22, 116 5-Fluorodeoxyuridine activity in liver (rat), 22, 116 cytotoxicity, 21, 211 elevation by fluoride (rat), 22, 116 in gastrointestinal tumor (human), 21, 723 Glucuronidation 5-Fluoro-2’-deoxyuridine 5’-diphosphate, intracellular, effect of 5-fluo- benzo[apyrene metabolism (rat), 22, 451 rodeoxyuridine, 21, 211 rates, 7-hydroxycoumarin (rat), 22, 509 5-Fluoro-2’-deoxyuridine 5’-triphosphate, intracellular, effect of 5-fluo- Glutamate-stimulated calcium uptake (rat, mouse), 22, 99 rodeoxyuridine, 21, 211 y-Glutamylcysteinylglycine, analogues (hydra), 21, 629 Fluorodeoxyuridylate, formation, 21, 224 Glutathione 5-Fluoro-5’-O-nitro-2’-deoxyuridine, cytotoxicity in L1210 cultures, 22, alkyl halide metabolism (rat), 22, 745 760 receptor, peptide interaction (hydra), 21, 629 5-Fluorouracil Glycine, rescue effects in methotrexate-treated cells (human), 21, 718 DNA incorporation, 21, 211 Glycogen phosphorylase, conversion B to A in C6 glioma cells, 22, 395 effect on colon carcinoma cells in culture (human), 21, 468 Growth inhibition, cellular (human), 21, 718 interaction with N-(phosphonacetyl)-L-aspartate, 21, 224 GTP -methotrexate combination, action in colon adenocarcinoma (hu- binding, regulatory protein (bovine), 21, 52 man), 22, 771 regulation, dopamine receptors (bovine), 21, 52 5-Fluorouridine, effect on colon carcinoma cells in culture (human), 21, GTPase 468 hormonal stimulation, 21, 336 SUBJECT INDEX 819

low Km, stimulation by inhibitors, 21, 336 agonist, effect on binding and biological response of gastric mucosal Guanine nucleotide(s) cells (guinea pig), 22, 33 -activated cardiac adenylate cyclase activity (rat), 22, 342 H, agonists, in polymorphonuclear neutrophils (human), 21, 78 alpha2-adrenergic receptors, 21, 17 H2 agonists, in polymorphonuclear neutrophils (human), 21, 78 effect H , antagonist on binding in purified platelet membranes (human), 21, 600 in polymorphonuclear neutrophils (human), 21, 78 on cardiac binding sites (rat), 21, 581 long-acting (rat, guinea pig), 21, 294 on pituitary dopamine receptors (porcine), 22, 290, 298 H2 antagonist on prostaglandin E2 receptors in adipocytes (hamster), 22, 320 effect on binding and biological reponse of gastric mucosa cells interaction with cardiac receptors (rat), 21, 570 (guinea pig), 22, 41 receptor in polymorphonuclear neutrophils (human), 21, 78 regulation (guinea pig, bovine), 21, 329 interaction with gastric mucosal cells (guinea pig), 22, 33, 41 regulation (rat), 22, 532 -mediated adenylate cyclase stimulation in myocardium (human), -sensitive adenylate cyclase, effects of sulihydryl groups (dog), 22, 21, 671 595 receptors Guanosine-5’-triphosphate, effect on dopamine receptors (b*ine), 21, characterization in van deferens (mouse), 22, 602 52 in polymorphonuclear neutrophils (human), 21, 78 Guanyl nucleotides, renal cortex (rat), 22, 589 myocardial (human), 21, 671 Guanylate cyclase, myometrial (guinea pig), 21, 654 surface, in promyelocytic leukemia cells (human), 22, 547 Histone, thymus H effect of methylmercury(II) (calf), 22, 121 formaldehyde cross-linking (calf), 22, 121 Haloethylnitrosoureas, selective cytotoxicity in carcinoma (rat), 21, 729 methylmercury complexes (calf), 22, 121 Halogen atoms, oxidation (rat), 22, 745 Histrionicotoxin Halothane actions at ion channels, 21, 343 effect on Ca2-ATPase in cardiac sarcoplasmic reticulum (bovine), binding to electrically excitable membranes (ray), 22, 82 22, 8 effect on neuromuscular transmission, 22, 565 reductive metabolism by cytochrome P-450 (human, rabbit), 21, 710 H202, generation by hepatic cytochrome P-450 (rat), 22, 465 Heart Hormone digitalis receptor, inhibition of ouabain binding (guinea pig), 22, 687 inhibition, adenylate cyclase, 21, 336 hypertrophy, effect on muscarinic receptors (rat), 21, 589 stimulation, GTPase, 21, 336 membrane Horseradish peroxidase-hydrogen peroxide oxidation of sulfite, 22, 732 adenylate cyclase activity (rat), 22, 342 Hybridization, blot muscarinic receptors (rat), 21, 581 DNA (mouse), 22, 779 microsomes mRNA (mouse), 22, 779 cytochrome P-450 activity (fish), 21, 517 Hybridoma, monoclonal antibodies, 21, 248 monooxygenase activity (fish), 21, 517 Hydra feeding receptor, 21, 629 mitochondrial ATPase, fluphenazine inhibition (bovine), 21, 415 Hydration activity, carbon dioxide, of skeletal muscle (cat), 22, 211 muscarinic cholinergic receptor, interaction with guanine nucleotide Hydrocarbon, polycyclic aromatic binding component (rat), 21, 570 epoxide stability, 22, 459 muscarinic receptors (rat), 21, 581, 589 stereoselective metabolism (rat), 22, 182 sarcoplasmic reticulum, effect of halothane (bovine), 22, 8 Hydrogen peroxide toxicity of anthracycline antineoplastic agents, 22, 471 hepatic microsomal metabolism (rabbit), 22, 471 Heat -horseradish peroxidase oxidation of sulfite, 22, 732 inactivation, receptors in brain (rat), 22, 327 Hydrolase, epoxide, activity in neonatal skin (rat), 21, 239 sensitivity, pituitary dopamine receptors (porcine), 22, 298 Hydroperoxide, fatty acid, soluble guanylate cyclase activation (guinea treatment, effect on dopamine receptors (bovine), 21, 52 pig), 21, 654 HeLa cell, 9-fl-n-arabinofuranosyl-2-fluoroadenine inhibition (human), Hydrophobic interaction, Ca2-calmodulin complex with calmodulin 21, 474 antagonists, 22, 403 Heme N-Hydroxyamphetamine destruction by benzyl hydrodisulfide (rat), 21, 464 effect on hepatic cytochrome P-450 (rat), 22, 465 metabolism, effect of organometals (rat), 21, 150 H202 generation (rat), 22, 465 oxygenase, effect of organometals (rat), 21, 150 4-Hydroxy-4-androstene-3,17-dione, inhibition ofestrogen biosynthesis, Hemoglobin, tetrameric, subunit selectivity (rabbit), 21, 1 21, 173 Hepatocyte y-Hydroxybutyrate, eleptogenic properties (mouse, guinea pig), 22, 431 isolated, S-adenosylhomocysteine binding (rat), 21, 108 7-Hydroxycoumarin, sulfation and glucuronidation rates (rat), 22, 509 methotrexate release (rat), 22, 493 6-Hydroxydopamine, cytotoxic effect, 21, 363, 368 Hepatoxocity, norcocaine nitroxide (rat, hamster), 21, 458 Hydroxyl group, rOle in phenylethanolamine N-methyltransferase sub- Herpes simplex virus strate activity, 22, 127 inhibition by (E)-5-(2-bromovinyl)-2’-deoxyuridine, 21, 432 Hydroxyl radical, production, 21, 262 selective inhibitors, 21, 217 Hydroxylase, tyrosine, induction by glucocorticoids (mouse), 22, 421 Heterogeneity N-Hydroxylase adenosine A, receptor binding in brain (rat, rabbit, guinea pig, calf, induction in liver (rat), 21, 449 human), 22, 250 modification in liver (rat), 21, 449 binding (cat), 22, 304 Hydroxylation, benzo[a]pyrene, 21, 248 species, adenosine receptor binding in brain (rat, rabbit, guinea pig, N-Hydroxynorcocaine, in vitro lipid peroxidation, 22, 529 calf, human), 22, 250 N-Hydroxyphentermine Histamine effect on hepatic cytochrome P-450 (rat), 22, 465 820 SUBJECT INDEX

phenyl-N-methyltransferase, 22, 725 N-hydroxyphentermine-continued H2O2 generation (rat), 22, 465 Plasmodium falciparum growth, by selected aromatic chelators, 22, phentermine N-oxidation to (rabbit), 22, 235 140 8-Hydroxyquinoline, antimalarial activity, 22, 140 platelet adenylate cyclase (human), 21, 609; 22, 574 Hyperthyroidism, effect on cardiac muscarmnic receptors (rat), 21, 589 platelet cyclic AMP generation (human), 21, 680 prostaglandin synthesis (toad), 21, 142 Hypertrophy, cardiac, effect on muscarmnic receptors (rat), 21, 589 Hypnotics, interaction with benzodiazepine receptors, 21, 320 protein kinase, 22, 408 Hypoglycemia, sulfonylureas, Ca2 ionophoretic activity (mouse), 22, protein synthesis in brain and liver (rat), 22, 706 715 quinone, hepatic (rat), 22, 451 Hypothalamus RNA polyadenylation, 22, 517 catecholamine uptake system (rat), 21, 374 skeletal muscle carbonic anhydrase (cat), 22, 211 synaptosomal protein carboxymethyltransferase (rat), 21, 181 synaptosomal protein carboxymethyltransferase (calf, rat), 21, 181 Hypothermia, effect on muscannic agonist binding (rat), 21, 594 Inhibitor Hypothyroidism adipocyte adenylate cyclase, 21, 336 effect on adipocytes (rat), 22, 109 calmodulin, in C6 glioma cells, 22, 395 effect on cardiac muscarinic receptors (rat), 21, 589 microtubular, effect on Ca2-transport ATPase, 22, 413 Hypoxia, leukemia cells, synergistic toxicity of misonidazole and sulfi- norepinephrine uptake, 21, 380 docyclophosphamide (mouse), 22, 175 tricyclic, dopamine, in striatum and hypothalamus (rat), 21, 374 Insulin I binding sites, in erythrocytes (frog), 22, 619 Ileum -like activity of oxytocin (rat), 22, 381 binding of f-endorphin, models (guinea pig), 22, 657 receptors field-stimulated (guinea pig), 21, 259 adipocyte, effects of adenosine (rat), 22, 614 Imidazolidines, X-ray structure, 21, 400 down-regulation (frog), 22, 619 Immunochemical quantitation, flavin-containing monooxygenase, 22, erythrocyte, regulation by insulin and concanavalin A (frog), 22, 787 619 Immunochemical staining, coupled with electrophoresis, 22, 787 regulation of insulin receptors in erythrocytes (frog), 22, 619 Immunochemistry resistance, oxytocin and (rat), 22, 381 cytochrome P-450 (rat), 21, 744, 753 secretion, inhibition by alpha2-adrenergic receptors (rat), 21, 648 liver microsomal epoxide hydrolase (human), 22, 190 sensitivity, modulation by adenosine (rat), 22, 614 Immunodiffusion, radial, measurement of cytochrome P-450 concentra- Intercalating drugs, cellular effects (mouse), 21, 739 tion (rat), 21, 753 5-Iodo-2’-deoxycytidine, antiherpes activity, 21, 217 Immunoprecipitation, monoamine oxidase B, 22, 500 (E)-5-(2-Iodovinyl)-2’-deoxycytidine, antiviral and antimetabolic prop- Immunoreactivity, antinucleoside (mouse), 21, 739 erties, 21, 217 Imprinting, neonatal, and hepatic cytochrome P-450 (rat), 21, 744 Ion Inactivation aziridinium, inhibition of norepinephrine uptake, 21, 380 heat, receptors in brain (rat), 22, 327 channel suicide acetylcholine receptor, meproadifen reaction with (frog), 22, 636 cytochrome P-450 (rat), 21, 166 activation, 22, 565 hepatic arylhydroxamic acid N,O-acyltransferase (hamster), 21, blockade, 21, 351; 22, 565 159 muscle membranes, 21, 351 Inelastic electron tunneling spectroscopy, interaction of acetylcholine neuroblastoma variants, 22, 196 and fl-methyl acetylcholine with alumina surface, 22, 678 nicotinic acetylcholine receptor, 21, 351 Inflammation, role of neutrophils (rat), 21, 688 nicotinic acetylcholine receptor (ray), 22, 82 Inhibition receptor (frog), 21, 637 acetylcholinesterase (ray), 22, 63 nickel, modulation (rat), 22, 335 S-adenosyl-L-methionine biosynthesis (rat), 22, 752 benzodiazepine receptor (mouse), 21, 618 adenylate cyclase role in adenylate cyclase inhibition (rat), 22, 589

by :i+ (mouse), 22, 274 transport, effect of anticonvulsant drugs, 22, 627 by Sc” (mouse), 22, 274 Ionophore in neuroblastoma cells, 21, 483 -a-aminobutyric acid complex, 21, 320 in renal cortex (rat), 22, 589 Ca2F opiate, 21, 483 effect on cyclic AMP, 22, 310 receptor-mediated (rat), 21, 570 hypoglycemic sulfonylureas (mouse), 22, 715 [“H]batrachotoxinin A 20-a-benzoate binding, 22, 627 Isomer, optical, methotrimeprazine, 21, 315 DNA, methotrexate (human), 21, 718 Isoproterenol, effect on cardiac adenylate cyclase activity (rat), 22,342 estrogen biosynthesis, 21, 173 Isosafrole human lymphoid, by antifolate BW3O1U, 22, 766 induction of cytochrome P-450 subpopulations (rat), 21, 527 insulin secretion, alpha2-adrenergic receptor (rat), 21, 648 induction of cytochrome P,-450 (mouse), 22, 779 leukemia L1210 cells, by acndine derivatives (mouse), 22, 486 Isozyme light-enhanced, ouabain binding to digitalis receptor (rat, guinea pig), cytochrome P-450, catalytic activity (rabbit), 22, 738 22, 687 mammalian ATP:L-methionine S-adenosyltransferase, differences in liver cytochrome P-450 (rat), 21, 464 active-site region (rat), 22, 752 magnesium-dependent, heart soluble mitochondrial ATPase (bo- purified microsomal, interaction with acet.anilide (rabbit), 21, 701 vine), 21, 415 magnesium transport (mouse), 22, 274 K metabolism, inhibition by antifolate BW3O1U (mouse), 22, 766 K depolarization (mouse), 22, 715 [3H]phencyclidine interactions with acetylcholine receptor channel KB cell (ray), 22, 72 dihydrofolate reductase (human), 21, 231 SUBJECT INDEX 821

methotrexate-resistant (human), 21, 231, 478 atives, 22, 486 Ketanserin Lipoproteins functional role (rat), 21, 301 free cholesterol transfer (human), 21, 694 3H-labeled high-density, free cholesterol transfer (human), 21, 694 binding properties (rat), 21, 301 low-density, free cholesterol transfer (human), 21, 694 selectivity (rat), 21, 301 Liposolubiity, adrenergic ligand in membranes (rat), 22, 5 Kidney Lipoxygenase adenylate cyclase-coupled alpha2-adrenergic receptors (rat), 22, 589 metabolism of arachidonic acid by neutrophils (rat), 21, 688 effect of adrenalectomy (rat), 22, 116 pathway, guanylate cyclase activation (guinea pig), 21, 654 glucose-6-phosphatase activity (rat), 22, 116 Liver microsomes, cysteine S-conjugate N-acetyltransferase (rat), 21, 444 N-acetyltransferase multiplicity (hamster), 21, 159 phenacetin toxicity, 22, 479 ATP concentration, effect of morphine (rat), 22, 706 Kinase cytochrome P-450 protein cadmium-sensitive (rat), 22, 795 activation in parotid gland (rat), 21, 121 inactivation (rat), 21, 166 cyclic AMP, 21, 121 induction with pregnenolone-16a-carbonitrile (rat), 21, 753 inhibition, 22, 408 inhibition by benzyl hydrodisulflde (rat), 21, 464 thymidylate, virus-coded, 21, 432 neonatal imprinting and (rat), 21, 744 Kinetics turnover (rat), 21, 744 N,O-acyltransferase inactivation (hamster), 21, 159 subpopulations, induction by phenobarbital, /3-naphthoflavone, aryihydroxamic acid, suicide inactivation (hamster), 21, 159 and isosafrole (rat), 21, 527 binding cytochrome P,-450, mRNA (mouse), 22, 779 association and dissociation (rat), 21, 57 effect of adrenalectomy (rat), 22, 116 warfarin to human serum albumin, 21, 100 enzymes, stereoselective metabolism of polycyclic aromatic hydro- benzo[a]pyrene metabolism (rat), 22, 451 carbon substrates (rat), 22, 182 [3H]flunitrazepam binding (rat), 21, 57 glucose-6-phosphatase activity (rat), 22, 116 opiate receptor binding (sheep), 22, 648 glucuronidation rates, 7-hydroxycoumarin (rat), 22, 509 Km, low, GTPase, 21, 336 microsomes arylamide N-hydroxylase (rat), 21, 449 L benzo[a]pyrene metabolism (rat), 22, 451 j3+ inhibition of adenylate cyclase (mouse), 22, 274 drug metabolism (rabbit), 22, 471 Labeling, selective, serotonin-2 receptors (rat), 21, 301 epoxide hydrolase (human), 22, 190 Lecithin, egg vesicles, 21, 694 ‘H Fourier transform NMR studies (rabbit), 21, 701 Lergotrile, effect on dopamine synthesis (rat), 21, 114 H2O2 generation (rat), 22, 465 Leucine enkephalin, ‘H-labeled inhibition of oxidative drug metabolism (rabbit), 22, 471 binding in vitro, 21, 548 metabolism of propyl halides (rat), 22, 745 effect of morphine on binding (rat), 21, 538 mixed-function oxidase (rat), 21, 150 Leukemia N-oxidation of phentermine (rabbit), 22, 235 cell, hypoxic, synergistic toxicity of misonidazole and sulfidocyclo- perfused, ethanol metabolism (rat), 21, 438 phosphamide (mouse), 22, 175 plasma membrane, S-adenosylhomocysteine binding (rat), 21, 108 L1210 cells protein synthesis inhibition by morphine (rat), 22, 706 cytotoxicity of 5-fluoro-5’-O-nitro-2’-deoxyuridine, 22, 760 reconstituted cytochrome P-450 (rabbit), 22, 235 inhibition by acridine derivatives (mouse), 22, 486 sulfation rates, 7-hydroxycoumarin (rat), 22, 509 promyelocytic cell line HL-60 (human), 22, 547 toxicity, norcocaine nitroxide (rat, hamster), 21, 458 Levitimide, inhibition of binding in heart (rat), 21, 581 Lung Levomepromazine, ring sulfoxidation, 21, 409 cytochrome P-450 Ligand isozymes, catalytic activity (rabbit), 22, 738 adrenergic 3-methylcholanthrene induction (rabbit), 22, 221 liposolubiity in membranes (rat), 22, 5 toxicity of 4-ipomeanol (rabbit), 22, 738 n-octanol:water (rat), 22, 5 Lymphoblast, cultured, deoxyuridine metabolism (human), 22, 166 delta- and mu-, chronic treatment, cross-tolerance, 22, 1 Lymphoid, inhibition by antifolate BW3O1U (human), 22, 766 3H-labeled, binding in caudate membrane (bovine), 21, 52 Lymphoma cell selective, for serotonin2 (rat), 21, 301 549, adenylate cyclase phenotypes (mouse), 22, 204 Lipid variant, adenylate cyclase activation, 22, 609 acidic, cerebroside sulfate, 21, 492 wild-type, adenylate cyclase activation, 22, 609 effects of ethanol, 22, 133 Lysosomatic amines, erythrocyte (frog), 22, 619 effect on adenylate cyclase activity, 21, 492 effect on opiate inhibition, 21, 492 M effect on opiates, 21, 492 Magnesium incorporation in neuroblastoma N18TG2 cells, 21, 492 alpha2-adrenergic receptors, 21, 17 in vitro peroxidation, 22, 529 -dependent inhibition, heart soluble mitochondrial ATPase (bovine), synthesis, adipocyte, effects of adenosine (rat), 22, 614 21, 415 thermotropic properties, 22, 133 regulation transition cooperativity, 22, 133 of adenylate cyclase (mouse), 22, 267, 274 vesicles, free cholesterol transfer (human), 21, 694 of beta-adrenergic receptor (mouse), 22, 267, 274 Lipogenesis, oxytocin stimulation (rat), 22, 381 transport, inhibition (mouse), 22, 274 Lipolysis, forskolin activation in adipocytes (rat), 22, 109 Malaria, human, treatment with lipophiic chelators, 22, 140 Lipophiic chelator, antimalarial activity, 22, 140 Manganese Lipophiic-hydrophiic balance, antileukemic activity of acridine deny- effect on adenylate cyclase (mouse), 22, 267 822 SUBJECT INDEX

Manganese-continued catecholamine-induced release from hepatocytes (rat), 22, 493 effect on opiate binding (rat), 21, 564 cellular effects, 21, 204 effect on receptor binding (mouse), 22, 267 cytotoxicity (human), 21, 718 Marcellomycin, effect on cytoplasmic RNA in erythroleukemia cells, in gastrointestinal tumor, 21, 723 22, 152 effect on dihydrofolate reductase activity (human), 21, 478 Mass spectrometry, 2Cf plasma desorption (rat), 21, 688 5-fluorouracil combination, action in colon adenocarcinoma (human), Membrane 22, 771 adipocyte, adrenergic ligand liposolubiity in (rat), 22, 5 lymphoblastoid resistance (human), 22, 766 -bound benzodiazepine receptors, kinetics of binding (rat), 21, 57 metabolic inhibition in mouse cell lines, 22, 766 brain, opiate binding (rat), 21, 564 metabolism, cellular (human), 21, 718 cardiac polyglutamates, accumulation in cells (human), 21, 718 adenylate cyclase activity (rat), 22, 342 -resistant KB cells (human), 21, 231, 478 muscarinic receptors (rat), 21, 581 -treated cells, rescue agents (human), 21, 718 caudate, “H-ligand binding sites (bovine), 21, 44, 52 Methotrimeprazine electrically excitable, interaction with N-alkyl analogues (ray), 22,82 enantiomers, differential stereoselectivity, 21, 315 erythrocyte, free cholesterol transfer (human), 21, 694 optical isomers, 21, 315 islet cell, adenylate cyclase (rat), 21, 648 ring sulfoxidation, 21, 409 lipid fl-Methyl acetylcholine, interaction with alumina surface, 22, 678 effects on adenylate cyclase, 22, 360 3-Methylcholanthrene, induction effects on receptors, 22, 360 cytochrome P,-450 (mouse), 22, 779 liver plasma, S-adenosylhomocysteine binding (rat), 21, 108 liver microsomes, benzo[a]pyrene metabolism (rat), 22, 451 model, fluidity, 22, 721 pulmonary cytochrome P-450 (rabbit), 22, 221 muscle, voltage-sensitive ion channels, 21, 351 Methylmercury II, effect on histones (calf), 22, 121 nerve, sodium channel binding sites, 21, 343 Methyltransferase, phospholipid, in liver plasma membranes (rat), 21, plasma, Ca2ttransport ATPase (human), 22, 413 108 platelet, purified, binding (human), 21, 600 Microcalorimetry, cephalosporin-human serum albumin complexes, 21, synaptosomal 92 binding sites (rat), 21, 57 Microsome cholinergic muscarinic receptor (cat), 22, 304 cardiac, cytochrome P-450 and monooxygenase activity (fish), 21, Meproadifen, effect on acetylcholine receptor (frog), 22, 636 517 Mesencephalic cell, primary culture, substance P derivative binding enzymes, comparison, 22, 787 (mouse), 22, 48 hepatic Metabolic activation arylamide N-hydroxylase (rat), 21, 449 antineoplastic agents (rabbit), 22, 471 benzo[a}pyrene metabolism (rat), 22, 451 phenacetin metabolites, 22, 479 drug metabolism (rabbit), 22, 471 Metabolic-intermediate complexes, cytochrome P-450 (rat), 21, 527 epoxide hydrolase (human), 22, 190 Metabolism ‘H Fourier transform NMR studies (rabbit), 21, 701 N-alkyl compounds, 21, 133 H2O2 generation (rat), 22, 465 anthracycline antineoplastic agents (rabbit), 22, 471 inhibition of oxidative drug metabolism (rabbit), 22, 471 benzo[a]pyrene (fish), 21, 517 metabolism of propyl halides (rat), 22, 745 benzo[apyrene, kinetic determinants (rat), 22, 451 3-methylcholanthrene-induced (rat), 22, 451 deoxyuridine, in lymphoblasts (human), 22, 166 reduction of gentian violet (rat), 22, 239 drugs renal, cysteine S-conjugate N-acetyltransferase (rat), 21, 444 in neonatal epidermis (rat), 21, 239 Misonidazole, cytotoxicity, synergism with sulfidocyclophosphamide sexual differences (rat), 21, 744 (mouse ), 22, 175 ethanol, in perfused liver (rat), 21, 438 Mitochondria, heart ATPase, fluphenazine inhibition (bovine), 21, 415 heme, effect of organometals (rat), 21, 150 Mitoxantrone, hepatic microsomal metabolism (rabbit), 22, 471 inhibition, by antifolate BW3O1U (mouse), 22, 766 Model membrane, fluidity, 22, 721 methotrexate, cellular (human), 21, 718 Molecular conformation, solid-state, 21, 409 peroxidase, 21, 133 Molecular orbital calculations, polycycic aromatic hydrocarbon epox- reductive, halothane, by cytochrome P-450 (human, rabbit), 21, 710 ide stability, 22, 459 stereoselective, chrysene 1,2-dihydriols (rat), 22, 182 Molecular shape analysis, 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187 Metabolite Molecular structure, 3-carbomethoxy rifamycin 5, 21, 394 active, chioramphenicol (rat), 21, 166 Monoamine oxidase arachidonic acid, stimulation of neuroblastoma adenylate cyclase, 21, B 664 immunoprecipitation, 22, 500 chlorpromazine, ring sulfoxidation, 21, 409 monoclonal antibody to, 22, 500 cocaine, hepatotoxicity (rat, hamster), 21, 458 pargyline labeling, 22, 500 methotrimeprazine, ring sulfoxidation, 21, 409 platelet (human), 22, 500 phenacetin, activation, 22, 479 separation of A and B, 22, 500 sulfoxide, effect on neuroleptic potency, 21, 409 Monoclonal antibody Methiodide, aceclidine, binding in brain (rat), 21, 594 distinction of monoamine oxidase A and B, 22, 500 Methionine adenosyltransferase, tumor and normal, substrate specific- hybridoma, 21, 248 ities (rat), 22, 752 to cytochrome P-4SOLM2 and P-450LM4, 21, 248 L-Methionine, analogues, substrate and inhibitory properties (rat), 22, to monoamine oxidase B (human), 22, 500 752 Monohydroxyaminotetralins Methotrexate enantiomeric, effect on dopamine binding (rat), 22, 281 analogues, 21, 231 racemic, effect on dopamine binding (rat), 22, 281 SUBJECT INDEX 823

Monooxygenase Nerve membrane, sodium channel binding sites, 21, 343 activity, in cardiac microsomes (fish), 21, 517 Neuroblastoma cells -like activity, of tetrameric hemoglobin (rabbit), 21, 1 cultured, adenylate cyclase, 21, 664 reconstituted system (rat), 21, 166 x glioma hybrid Morphine adenylate cyclase activity, 22, 360 effect on ATP concentration in brain and liver (rat), 22, 706 alpha2-adrenergic receptors, 21, 17 effect on binding of [3H]leucine enkephalin (rat), 21, 538 x glioma NG1O8-15 hybrid effect on blood pH, Po2, and Pco2 (rat), 22, 706 alpha2-adrenergic receptors, 21, 17 effect on calmodulin activity in brain (rat), 22, 389 opiate inhibition, 21, 483 effect on protein synthesis in brain and liver (rat), 22, 706 opiate receptor activity, 22, 1 receptors, and enkephalin receptors, allosteric coupling in vitro, 21, N18TG2 548 opiate inhibition, 21, 483 Morphology, cellular transformation (mouse), 21, 739 potentiation of opiate action, 21, 492 Mucosa, fundic, cells, interaction with histamine (guinea pig), 22, 33, serotonin uptake, 21, 362 41 tyrosine hydroxylase induction (mouse), 22, 421 Muscarinic receptor variant clones, characterization, 22, 196 binding, aceclidine and its methiodide (rat), 21, 594 Neuroleptic potency, effect of ring sulfoxidation, 21, 409 central (cat), 22, 304 Neuroleptics, effect on glycogen phosphorylase, 22, 395 cholinergic Neuromuscular blockade, pumiliotoxin-C, 22, 565 activation of phosphodiesterase, 22, 310 Neuromuscular junction, desensitization (frog), 22, 636 effect of phencyclidine (frog), 21, 637 Neuromuscular transmission, effect of meproadifen (frog), 22, 636 synaptosomal membrane (cat), 22, 304 Neuronal cell, culture (mouse), 22, 48 Muscle Neutrophil cloned cell line, BC3H-1 (mouse), 22, 258 formation of diarachidonyl diglyceride (rat), 21, 688 denervated (frog), 22, 636 functions (human), 21, 78 membrane, voltage-sensitive ion channels, 21, 351 peripheral (human), 22, 547 skeletal polymorphonuclear, histamine receptors (human), 21, 78 action potential (frog, ray), 22, 82 Nickel ion, modulation (rat), 22, 335 carbonic anhydrase, carbon dioxide hydration activity (cat), 22, Nicotine, binding in brain (mouse), 22, 554 211 Nicotinic acid, prostaglandins, 21, 336 twitch Nicotimc antagonists, binding, 22, 565 effect of meproadifen (frog), 22, 636 Nicotinic receptor effect of N-alkyl analogues of amantadine (frog), 22, 82 binding in brain (mouse), 22, 554 Mutagenic effect, sodium channels, 22, 196 effect of phencyclidine (frog), 21, 637 Mutagenicity, Ames test, 21, 187 5-Nitro-2’-deoxycytidine, antiherpes activity, 21, 217 Mutant, somatic, genetic complementation (mouse), 22, 204 Nitrogen Mutation, single-gene (mouse), 22, 204 bifunctional mustards, carcinoma cell line resistance (rat), 21, 729 Myocardium, histamine-mediated adenylate cyclase stimulation (hu- oxidation, cytochrome P-450-dependent (rabbit), 22, 235 man), 21, 671 Nitrosoureas, selective cytotoxicity in carcinoma (rat), 21, 729 Myometrium Nonlinear least-squares curve fitting, insulin binding study (frog), 22, carbachol, phospholipase A2 activation (guinea pig), 21, 654 619 guanylate cyclase (guinea pig), 21, 654 Norcocaine nitroxide induced hepatotoxicity (rat, hamster), 21, 458 N in vitro lipid peroxidation, 22, 529 NADH dehydrogenase, hepatic microsomal (rabbit), 22, 471 Norepinephrine NADPH inhibition of serotonin uptake, 21, 362 -cytochrome P-450 reductase, hepatic microsomal (rabbit), 22, 471 uptake oxidation, hepatic microsomal (rabbit), 22, 471 in pheochromocytoma cells, 21, 368 Na,K-ATPase inhibition by xylamine, 21, 380 ADP-sensitive, phosphoenzyme-rich (electric eel), 22, 693 Norfenfluramine, conformationally defined analogues, 22, 127 conversion of ADP-sensitive to K-sensitive phosphorylated forms Nuclear envelope, epoxide hydratase, inducibility (rat), 21, 511 (electric eel), 22, 693 Nuclear magnetic resonance oligomycin interaction (electric eel), 22, 693 cephalosporin-human serum albumin complexes, 21, 92 phosphorylated intermediate ‘H ADP-sensitive (electric eel), 22, 693 3-carbomethoxy rifamycin 5, 21, 394 interaction with ouabain (electric eel), 22, 700 Fourier transform, cytochrome P-450 (rabbit), 21, 701 Naloxone Nuclear structure, effect of nitrosoureas (rat), 21, 729 3H-labeled, binding in brain (rat), 22, 349 Nucleoside prevention of acute effect of morphine on protein synthesis in brain adenine, effects on RNA synthesis, 22, 517 and liver (rat), 22, 706 molecular associations with Adriamycin, 22, 158 Naphthalenesulfonamide derivatives Nucleotide(s) effect on Ca2-calinodulin complex, 22, 403 guanine phosphorylation modulation, 22,408 -activated cardiac adenylate cyclase activity (rat), 22, 342 $-Naphthoflavone, induction of cytochrome P-450 subpopulations alpha2-adrenergic receptors, 21, 17 (rat), 21, 527 effect on cardiac binding sites (rat), 21, 581 Narcotic analgesia, 21, 548 effect on pituitary dopamine receptors (porcine), 22, 290, 298 Neonate, imprinting, and hepatic cytochrome P-450 (rat), 21, 744 effect on prostaglandin E2 receptors in adipocytes (hamster), 22, Nephrotoxicity, phenacetin-induced, 22, 479 320 824 SUBJECT INDEX

Nucleotide-continued Overlap, with fused ring opiates, 22, 667 guanine-continued Oxidase interaction with cardiac receptors (rat), 21, 570 cytochrome P-450, N-oxidation of phentermine (rabbit), 22, 235 receptor regulation (guinea pig, bovine), 21, 329 mixed-function receptor regulation (rat), 22, 532 benzo[a]pyrene oxygenation, 21, 248 guanyl, renal cortex (rat), 22, 589 hepatic (rat), 21, 150 levels in cells treated with 5-fluorodeoxyuridine, 21, 211 in neonatal skin (rat), 21, 239 molecular association with Adriamycin, 22, 158 monamine pyrimidine, biosynthesis, 21, 224 B, immunoprecipitation, 22, 500 Nucleus B, monoclonal antibody to, 22, 500 histones, effect of methylmercury (II) (calf), 22, 121 B, pargyline labeling, 22, 500 thymus, formaldehyde cross-linking (calf), 22, 121 platelet (human), 22, 500 separation of A and B, 22, 500 0 Oxidation Oligomycin, inhibition of ADP-sensitive K-sensitive change (electric horseradish peroxidase-hydrogen peroxide, of sulfite, 22, 732 eel), 22, 693 NADPH, hepatic microsomal (rabbit), 22, 471 Opiate nitrogen, cytochrome P-450-dependent (rabbit), 22, 235 action, potentiation in neuroblastoma N18TG2 cells, 21, 492 phentermine, cytochrome P-450-dependent (rabbit), 22, 235 addiction, effects on calmodulin activity (rat), 22, 389 N-Oxidation, phentermine, by cytochrome P-450 oxidase system (rab- agonist bit), 22, 235 binding model (rat), 22, 349 Oxine derivatives, antimalarial activity, 22, 140 potency and efficacy, 21, 483 Oxotremorine alkaloids, in brain (rat), 21, 564 binding in brain (rat), 21, 594 analgesia (rat), 21, 272 3H-labeled, binding in heart (rat), 21, 581, 589 antagonist, binding model (rat), 22, 349 Oxygenase, heme, effect of organometals (rat), 21, 150 chronic treatment, effect on opiate receptor activity, 22, 1 Oxytocin delta-, receptor site, 21, 266 action in adipocytes (rat), 22, 381 drugs, inhibition of phencycidine binding (ray), 22, 72 adipocyte receptors (rat), 22, 381 effect, chronic, 21, 483 analogues, action in adipocytes (rat), 22, 381 inhibition glucose transport (rat), 22, 381 adenylate cyclase activity, 21, 483 insulin-like activity (rat), 22, 381 adenylate cyclase, Na and GTP effect, 21, 483 insulin resistance (rat), 22, 381 interaction with phencyclidine (ray), 22, 72 stimulation of glucose oxidation (rat), 22, 381 kappa-, receptor site, 21, 266 stimulation of lipogenesis (rat), 22, 381 mu-, receptor site, 21, 266 stimulation of pyruvate dehydrogenase (rat), 22, 381 receptor binding, 21, 483, 492 P binding in brain (rat), 21, 564 binding models (rat), 21, 272 Pancreas islets binding sites, 21, 266 calcium transport (mouse), 22, 715 caudate nucleus, etorphine binding (sheep), 22, 648 cyclic AMP generation (rat), 21, 648 delta, 21, 558 Parinaric acid, absorbance in lipid, 22, 133 desensitization, 22, 1 Pargyline, labeling of monoamine oxidase B, 22, 500 down regulation, time course, 22, 1 Parotid cell, alpha,-adrenergic stimulation (rat), 21, 128 effect relationship (rat), 21, 272 Parotid gland in neuroblastoma x glioma NG1O8-15 hybrid cells, 22, 1 phosphatidylinositol-phosphatidic acid turnover (rat), 21, 128 in vivo binding (rat), 21, 272 protein kinase activation (rat), 21, 121 membrane lipid effects, 22, 360 Partition coefficient, adrenergic ligand liposolubiity (rat), 22, 5 multiple (rat), 21, 564 Peptide multiple, coupling in vitro, 21, 548 interaction of glutathione receptor of hydra, 21, 629 multiple, in brain (rat), 21, 538 opioid multiple sites, 21, 266 binding in brain (rat), 21, 564 various brain areas (rat), 22, 389 interaction with calmodulin (bovine), 21, 86 sigma receptor site, 21, 266 Permeability, potassium (frog), 21, 637 tetrapeptide, conformational-energy studies, 22, 667 Pergolide, effect on dopamine synthesis (rat), 21, 114 Optical isomer, methotrimeprazine, 21, 315 Peroxidase metabolism, 21, 133 Opioid Peroxidation, lipid, in vitro, 22, 529 peptides Pharmacological shift ratio, definition, 22, 580 binding in brain (rat), 21, 564 Pharmacophore, benzodiazepine, 22, 11 interaction with /3-endorphin (bovine), 21, 86 Phase transitions, dipalmitoylphosphatidylcholine, 22, 133 receptor Phenacetin metabolites, activation, 22, 479 allosteric effects, 21, 548 Phencycidine allosteric effects (rat), 21, 538 analogues (frog), 21, 637 binding, two-state model (rat), 22, 349 binding to acetylcholine receptor (ray), 22, 72 Organometals, effect on heme metabolism (rat), 21, 150 behavioral effects (frog), 21, 637 Ouabain binding to channel sites (ray), 22, 72 binding to digitalis receptor (rat, guinea pig), 22, 687 3H-labeled interaction with phosphorylated intermediate ofNa,K-ATPase (elec- binding to channel sites (ray), 22, 63 tric eel), 22, 700 interaction with nicrotinic acetylcholine receptor channel (ray), SUBJECT INDEX 825

22, 72 adenylate cyclase (human), 22, 574 potassium permeability (frog), 21,637 alpha2-adrenergic receptors (human), 21, 36, 609; 22, 574 Phenobarbital calcium mobilization, effect of trifluoperazine (human), 21, 422 enzyme induction (rat), 21, 511 inhibition of aggregation (human), 21, 680 induction of cytochrome P-450 subpopulations (rat), 21, 527 membranes, purified, binding (human), 21, 600 induction of hepatic cytochrome P450 (rat), 21, 753 monoamine oxidase, monoclonal antibody to (human), 22, 500 Phenotype, adenylate cyclase, in S49 lymphoma cells (mouse), 22, 204 protein phosphorylation, effect of trifluoperazine (human), 21, 422 Phenoxybenzamine, dopamine receptor alkylation (bovine), 21, 44 secretion and aggregation, effect of trifluoperazine (human), 21, 422 Phentermine storage of biogenic amines (human), 22, 94 oxidation, cytochrome P-450-dependent (rabbit), 22, 235 Pollutants, environmental, effect on heme metabolism (rat), 21, 150 N-oxidation, by cytochrome P-450 oxidase system (rabbit), 22, 235 Polyadenylation, RNA, inhibition, 22, 517 1-(X-Phenyl)-3,3-dialkyltriazenes Poly(A)-RNA, synthesis, 22, 152 Ames test, 21, 187 Polycyclic aromatic hydrocarbons antitumor activity, 21, 187 carcinogenic, epoxide stability, 22, 459 Phenylethanolamine, trifluoromethyl-substituted, 22, 127 stereoselective metabolism (rat), 22, 182 Phenylethanolamine N-methyltransferase Polyglutamates, methotrexate, accumulation in cells (human), 21, 718 inhibition, 22, 127 Polymerase substrates, 22, 127 DNA, inhibition (human), 21, 474 Phenylethylamine DNA-dependent RNA, inhibition by rifamycin, 21, 394 conformationally defined analogues, 22, 127 Polysome pharmacological activity, 22, 725 brain, effect of morphine (rat), 22, 706 Phenylisopropyladenosine, effects on glucose transport (rat), 22, 614 liver, effect of morphine (rat), 22, 706 Phenyl-N-methyltransferase Potassium inhibition, 22, 725 fluxes, in erythrocytes (turkey), 21, 503 substrate activity, 22, 725 permeability (frog), 21, 637 N-Phenylnaphthylamine, in study of membrane fluidity, 22, 721 -stimulated calcium uptake (rat, mouse), 22, 99 Phenyltriazenes, molecular shape analysis, 21, 187 Potentiation, opiate action, in neuroblastoma N18TG2 cells, 21, 492 Pheochromocytoma cells Prazosin, 3H-labeled norepinephrine uptake, 21, 368 alpha,-adrenergic receptor (mouse), 22, 258 serotonin uptake, 21, 368 binding in renal cortex (rat), 22, 532 Phosphatidic acid, turnover in parotid cells (rat), 21, 128 Pregnenolone-16a-carbonitrile Phosphatidylinositol, turnover in parotid cells (rat), 21, 128 effect on hepatic tyrosine aminotransferase (rat), 21, 753 Phosphodiesterase induction of hepatic cytochrome P-450 (rat), 21, 753 Ca2-dependent activation, 22, 310 Prolactin secretion muscarinic cholinergic receptor-mediated activation, 22, 310 anterior pituitary gland (porcine), 22, 298 Phospholipid control (porcine), 22, 290 binding of 1-chloro-2,2,2-trifluoroethyl radical (human, rabbit), 21, n-Propylapomorphine, 3H-labeled, binding in pituitary (porcine), 22, 710 290, 298 methyltransferase, in liver plasma membranes (rat), 21, 108 N-n-Propylapomorphine, effect on dopamine synthesis (rat), 21, 114 vesicles, egg lecithin (human), 21, 694 5-Propyl-2’-deoxycytidine, antiherpes activity, 21, 217 N-(Phosphonacetyl)-L-aspartate, interaction with 5-fluorouracil, 21, Propyl $-carboline-3-carboxylate, 3H-labeled, binding (mouse), 21, 618 224 Propyl halides, metabolism in liver (rat), 22, 745 5-Phosphoribosyl-1-pyrophosphate, effect of methotrexate-5-fluorour- N-n-Propyl-3-(hydroxyphenyl)-piperidine, effect on dopamine synthe- acil on concentrations in colon xenografts (human), 22, 771 sis (rat), 21, 114 Phosphorylase, glycogen, conversion B to A in C6 glioma cells, 22, 395 3,3’-[(Propylimino)di-2,1-ethanediyl]bis[phenol], effect on dopamine Phosphorylated intermediate synthesis (rat), 21, 114 ADP-sensitive, in Na,K-ATPase preparation (electric eel), 22, 693 Prostacyclin, stimulation of cyclic AMP in cultured neuroblastoma, 21, Na,K-ATPase, interaction with ouabain (electric eel), 22, 700 664 Phosphorylation Prostaglandin Ca24-calmodulin-dependent, 22, 408 activation of platelet adenylate cyclase (human), 21, 680 protein, in human platelets, 21, 422 biosynthesis, N-alkylation during, 21, 133 Photoaffinity labeling E, immunoreactiye (toad), 21, 142 erythrocytes (turkey), 21, 503 E2 sparing of fI-carboline binding (mouse), 21, 618 binding regulation (hamster), 22, 320 Picrotoxin binding sites, in brain (rat), 22, 327 receptor in adipocytes (hamster), 22, 320 Picrotoxinin, structure-activity relationships (mouse, guinea pig), 22, effect on cultured thyroid cells (porcine), 21, 66 444 inhibition of platelet aggregation (human), 21, 680 Piocarpine binding in heart (rat), 21, 581 nictotinic acid, 21, 336 Pituitary gland receptors anterior in promyelocytic leukemia cells (human), 22, 547 dopamine receptor (porcine), 22, 290, 298 membrane lipid effects, 22, 360 prolactin secretion (porcine), 22, 298 stimulation of cyclic AMP in cultured neuroblastoma, 21, 664 effects on hepatic cytochrome P-450 (rat), 22, 795 synthesis, inhibition (toad), 21, 142 Plasma desorption, 252Cf, mass spectrometry (rat), 21, 688 synthetase Plasma membrane, Ca2-transport ATPase (human), 22, 413 -catalyzed activation of phenacetin metabolites, 22, 479 Plasmodium falciparum, inhibition by selected aromatic chelators, 22, co-oxidation, 21, 133 140 Protein Plasticity, synaptic, 21, 280 brain, synthesis inhibition by morphine (rat), 22, 706 Platelet(s) carboxy O-methylation, 21, 181 826 SUBJECT INDEX

Protein-continued temperature dependence of interaction (rat), 22, 20 coupling, adenylate cyclase, magnesium regulation (mouse), 22, 267 binding nase $-endorphin models, 22, 657 activation in parotid gland (rat), 21, 121 guamne nucleotide regulation (hamster), 22, 320 cyclic AMP (rat), 21, 121 monovalent cations (hamster), 22, 320 inhibition, 22, 408 central nervous system, in vitro, 21, 315 liver, synthesis inhibition by morphine (rat), 22, 706 cholinergic muscarinic (mouse), 22, 554 molecular association with Adriamycin, 22, 158 synaptosomal membrane (cat), 22, 304 phosphorylation, in human platelets, 21, 422 cholinergic nicotinic (mouse), 22, 554 synaptosomal, carboxymethyltransferase (calf, rat), 21, 181 complexes, in brain (rat), 22, 327 Proteolysis, $-endorphin model peptides, 22, 657 coupling Proton gradient, role in biogenic amine storage in platelets (human), adenylate cyclase (bovine), 21, 52 22, 94 adenylate cyclase, allozyme hypothesis, 22, 580 Psychotropic drugs, inhibition of phencyclidine binding (ray), 22, 72 N-ethylmaleimide (rat), 21, 570 Pumiliotoxin-C, effect on neuromuscular transmission, 22, 565 cross-linking, 21, 558 Pyrimidine -cyclase coupling (mouse), 22, 204 antifolate derivative, metabolic inhibition (mouse), 22, 766 cyclic AMP, in erythrocytes (turkey), 21, 503 fluorinated derivative, cytoxicity in L1210 cultures, 22, 760 digitalis, light-enhanced inhibition of binding (rat, guinea pig), 22, nucleotide, biosynthesis, 21, 224 687 Pyrromycin, effect on cytoplasmic RNA in erythroleukemia cells, 22, dopamine 152 affinity states (porcine), 22, 298 Pyruvate dehydrogenase, oxytocin stimulation (rat), 22, 381 anterior pituitary gland (porcine), 22, 290, 298 D-1, characterization (rat), 22, 281 Q D-2 (bovine), 21, 44, 52 Quantum chemical analysis, structure-activity relationships, 22, 525 D-3 (bovine), 21, 44, 52 Quantum mechanical analysis, clonidine, 21,400 subtypes (bovine), 21, 44, 52 Quaternary ammomum two affinity states (porcine), 22, 290 agonists and antagonists (ray), 22, 63 -drug interactions, nonspecific, 22, 725 drugs, interactions in Torpedo electric organ, 22, 63 -effector coupling, in platelets (human), 21, 609 Quinone inhibition, hepatic (rat), 22, 451 estrogen, translocation by SKF 525-A (rat), 21, 533 Quinuclidinyl benzilate [3Hjetorphine, binding in vivo (rat), 21, 272 binding in brain (mouse), 22, 554 glutathione, peptide interaction (hydra), 21, 629 binding in heart (rat), 21, 589 guanine nucleotide regulation (rat), 22, 532 ‘H-labeled histamine binding in astrocytoma cells (human), 22, 310 characterization in vas deferens (mouse), 22, 602 binding in heart (rat), 21, 581 in polymorphonuclear neutrophils (human), 21, 78 L-Quinuclidinyl benzilate, 3H-labeled, heterogeneity of binding sites in myocardial (human), 21, 671 synaptosomal membrane (cat), 22, 304 sensitivity to H, and H2 agonists and antagonists (mouse), 22, 602 inhibition of platelet adenylate cyclase (human), 22, 574 R insulin’ Radical adipocyte, effects of adenosine (rat), 22, 614 free, carbon-centered (rat), 22, 239 erythrocyte, regulation by insulin and concanavalin A (frog), 22, hydroxyl, production, 21, 262 619 Radioligand binding, computer modeling, 21, 5 interactions, thermodynamics (rat, rabbit, guinea pig, caff, human), Receptor 22, 250 acetylcholine ionic channel (frog), 21, 637 drug specificity (ray), 22, 63 kinetics, reserve, 22, 369 in soleus muscle (rat), 22, 565 -mediated inhibition, adenylate cyclase (rat), 21, 570 ionic channel (frog), 22, 636 multiple, in brain (rat), 22, 327 neuromuscular junction (frog), 22, 636 muscarinic nicotinic, 21, 351 antiestrogen interaction (rat), 21, 287 adenosine A, binding of acecidine and its methiodide (rat), 21, 594 binding heterogeneity (rat, rabbit, guinea pig, calf, human), 22,250 cardiac (rat), 21, 581, 589 binding in brain (guinea pig, bovine), 21, 329 central (cat), 22, 304 adenylate cyclase-coupled, anterior pituitary gland (porcine), 22, 298 muscarinic cholinergic adrenergic, see Adrenergic receptor activation of phosphodiesterase, 22, 310 y-aminobutyric acid, modulation of cation binding sites (rat), 22, 327 characterization (porcine), 21, 66 auto-, in dopamine synthesis (rat), 21, 114 effect of phencycidine (frog), 21, 637 autonomic, in submandibular gland (rat), 21, 27 interaction with guanine nucleotide binding component (rat), 21, benzodiazepine 570 y-aminobutyric acid regulation (mouse), 21, 618 in vivo regulation (chick), 21, 280 chloride channel regulation (mouse), 21, 618 on cultured thyroid cells (porcine), 21, 66, 73 heterogeneity (mouse), 21, 618 nicotinic in brain (rat), 22, 327 effect of N-alkyl analogues of amantadine (frog, ray), 22, 82 interaction with barbiturates, 21, 320 effect of phencycidine (frog), 21, 637 interconvertible conformations (rat), 21, 57 nicotinic acetylcholine ion regulation (mouse), 21, 618 binding sites (ray), 22, 72 membrane-bound (rat), 21, 57 channel, interactions with {‘3H]phencyclidine (ray), 22, 72 SUBJECT INDEX 827

ion channel, 21, 351 cytochrome P,-450 (mouse), 22, 779 ionic channels, interaction with N-alkyl analogues of amantadine effect of anthracyclines, 22, 152 (ray), 22, 82 nuclear neuromuscular (frog), 22, 636 colon carcinoma cells in culture (human), 21, 468 receptor/channel, binding (ray), 22, 63 transport, 22, 152 nicotinic cholinergic, in brain (rat), 22, 56 polyadenylation, inhibition, 22, 517 occupancy/effect relationship, 22, 574 polymerase, DNA-dependent, inhibition by rifamycin, 21, 394 opiate synthesis binding, 21, 483, 492 adenovirus, 22, 517 binding, effect relationship (rat), 21, 272 effects of ademne nucleosides, 22, 517 binding in brain (rat), 21, 564 in cultured colon carcinoma cells (human), 21, 468 binding models (rat), 21, 272 total, effect of anthracyclines, 22, 152 binding sites, 21, 266 R0t analysis, hepatic cytochrome P,-450 (mouse), 22, 779 caudate nucleus, etorphine binding (sheep), 22, 648 RU-24926, see 3,3’-[(Propylimino)di-2,1-ethanediyl]bis[phenol] delta, 21, 558 desensitization, 22, 1 S down regulation, time course, 22, 1 in neuroblastoma x glioma NG1O8-15 hybrid cells, 22, 1 5180 AT/3000 cell, dihydrofolate reductase (mouse), 21, 231 membrane lipid effects, 22, 360 Sarcoplasmic reticulum, cardiac multiple (rat), 21, 564 Ca2-ATPase (bovine), 22, 8 multiple, coupling in vitro, 21, 548 effect of halothane (bovine), 22, 8 multiple, in brain (rat), 21, 538 Saxitoxin multiple sites, 21, 266 binding site, structure, 21, 343 various brain areas (rat), 22, 389 nonspecific binding, 21, 343 opioid receptor, 21, 343 allosteric effects, 21, 548 Sc”4, inhibition of adenylate cyclase (mouse), 22, 274 allosteric effects (rat), 21, 538 Scatchard linearization, 21, 564 two-state binding model (rat), 22, 349 Secretin, effect on cardiac adenylate cyclase activity (rat), 22, 342 oxytocin, adipocyte (rat), 22, 381 Secretion presynaptic, conformational requirements, 21, 259 enzyme prostaglandin in parotid gland (rat), 21, 121 E2, adipocyte (hamster), 22, 320 regulation (rat), 21, 121 in promyelocytic leukemia cells (human), 22, 547 prolactin membrane lipid effects, 22, 360 anterior pituitary gland (porcine), 22, 298 regulation control (porcine), 22, 290 cations (guinea pig, bovine), 21, 329 stimulus-induced, in human platelets, 21, 422 guanine nucleotide (guinea pig, bovine), 21, 329 Secretory granule, isolated, calcium transport (mouse), 22, 715 saxitoxin, 21, 343 Sedatives, interaction with benzodiazepine receptors, 21, 320 serotonin, characterization in brain (rat), 22, 243 Selectivity site colon xenografts (human), 22, 771 delta-opiate, 21, 266 for delta opiate receptor, dimeric enkephalins, 21, 558 kappa-opiate, 21, 266 subunit, in tetrameric hemoglobin (rabbit), 21, 1 mu-opiate, 21, 266 Sensitivity sigma-opiate, 21, 266 heat, pituitary dopamine receptors (porcine), 22, 298 sodium regulation (rat), 22, 532 insulin, modulation by adenosine (rat), 22, 614 substance P, in mesencephalic cells (mouse), 22,48 Serotonin subtypes, computer modeling method for binding data, 21, 5 receptor, characterization in brain (rat), 22, 243 surface, for histamine (human), 22, 547 uptake, characterization, 21, 362, 368 Torpedo electric organ, 22, 63, 72 Serotonin-2 turnover in cultured thyroid cells (porcine), 21, 73 binding sites, selective 3H-ligand for (rat), 21, 301 Rectification, delayed (frog), 21, 637 receptor binding sites (rat), 21, 301 Reductase Serum, human cytochrome P-450, hepatic microsomal (rabbit), 22, 471 albumin, characterization of drug binding area, 21, 387 ribonucleotide, inhibition (human), 21, 474 binding to warfarin, 21, 100 Reduction, microsomal, gentian violet (rat), 22, 239 interaction with cephalosporins, 21, 92 Regulation, enzyme secretion in parotid gland (rat), 21, 121 Sex differentiation, cytochrome P-450 (rat), 22, 795 Regulatory site, antagonist, 22, 231 Sexual differences, drug metabolism (rat), 21, 744 Relaxation rates, T,, substrate-cytochrome P-450 complexes (rabbit), Skeletal muscle 21, 701 action potential (frog, ray), 22, 82 Renal cortex carbonic anhydrase, carbon dioxide hydration activity (cat), 22, 211 adenylate cyclase-coupled alpha2-adrenergic receptors (rat), 22, 589 SKF 525-A, see $-Diethylaminoethyl-2,2-diphenylpentanoate alpha-adrenergic receptors (rat), 22, 532 SKF 10047, binding sites, 21, 266 Ribonucleotide reductase, inhibition (human), 21, 474 Skin, neonatal, drug metabolism (rat), 21, 239 Rifamycin, C(3) derivatives, 21, 394 Sodium Ho 5-4864, 3H-labeled, characterization of benzodiazepine binding sites channel (rat), 22, 26 batrachotoxin binding, 22, 627 RNA binding site in nerve membrane, 21, 343 messenger conformation, 21, 343 828 SUBJECT INDEX

Sodium-continued 22, 211 channel-continued Sulfonylureas, hypoglycemic, Ca2 ionophoretic activity (mouse), 22, mutagenic effect, 22, 196 715 neuroblastoma variants, 22, 196 Sulfoxidation variants, 22, 196 effect on neuroleptic potency of chlorpromazine, 21, 409 effect on agonist and antagonist interactions with platelet alpha2- effect on neuroleptic potency of methotrimeprazine, 21, 409 adrenergic receptor (human), 21, 609 Sulfoxide, metabolites, 21, 409 effect on binding in purified platelet membranes (human), 21, 600 Sulfur dioxide, aqueous, sulfur trioxide radical anion, 22, 732 fluxes, in erythrocytes (turkey), 21, 503 Sulfur trioxide, radical anion, direct detection during oxidation of ion, role in adenylate cyclase inhibition (rat), 22, 589 sulfite, 22, 732 regulation of receptors (rat), 22, 532 Superoxide Solubiity, lipid, ethanol, 22, 133 hepatic microsomal (rabbit), 22, 471 Solubilization, serotonin receptors in brain (rat), 22, 243 spin-trapped adducts, 21, 262 Somatostatin, effect on polymorphorphonuclear neutrophils (human), Synaptic plasticity, 21, 280 21, 78 Synaptosome Species heterogeneity, adenosine receptor binding (rat, rabbit, guinea calcium uptake (rat, mouse), 22, 99 pig, calf, human), 22, 250 hypothalamic (rat), 21, 181 Spectroscopy, pulmonary cytochrome P-450 (rabbit), 22, 221 uptake system, 21, 374 Spin trap, superoxide, 21, 262 membrane Spiperone, binding in brain (rat), 22, 243 cholinergic muscarmnic receptor (cat), 22, 304 Spiroperidol, “H-labeled potential (rat, mouse), 22, 99 binding in pituitary (porcine), 22, 290, 298 striatal, uptake system (rat), 21, 374 binding to caudate nucleus (calf), 22, 281 Synergism, cytotoxic, misonidazole and sulfidocyclophosphamide dopamine receptor binding (bovine), 21, 44, 52 (mouse), 22, 175 Stability, epoxide, polycyclic aromatic hydrocarbons, 22, 459 Synthetase, prostaglandin, co-oxidation, 21, 133 Statistical analysis, computer modeling method, for radioligand binding Synthesis, prostaglandin, inhibition (toad), 21, 142 data, 21, 5 Stenosis, aortic, effect on cardiac muscarmnic receptors (rat), 21, 589 T Stenotomus chrysops, cytochrome P-450 and monooxygenase activity Tamoxifen binding, cooperativity studies (rat), 21, 287 in cardiac microsomes, 21, 517 Temperature Stereoselectivity dependence, benzodiazepine-receptor interaction (rat), 22, 20 differential, methotrimeprazine enantiomers, 21, 315 effect on [“Hiflunitrazepam binding (rat), 21, 57 metabolism , chrysene 1,2-dihydriols (rat), 22, 182 Terbium fluorescence, 22, 105 Stereospecificity, carbomethoxy at position 10, 21, 196 2,3,7,8-Tetrachlorodibenzo-p-dioxin, induction of cytochrome P,-450 Stilbene oxide, trans-, enzyme induction (rat), 21, 511 mRNA (mouse), 22, 779 Striatum, catecholamine uptake system (rat), 21, 374 Tetrahydro-fJ-carboline, effect on membrane fluidity, 22, 721 Structure-activity relationship Tetramethylammonium, agonist action (ray), 22, 63 alkyl-substituted -y-butyrolactones (mouse, guinea pig), 22, 444 Tetrapeptide, opiate, conformational-energy studies, 22, 667 alkyl-substituted succinimides (mouse, guinea pig), 22, 444 Thermodynamics amantadine (ray), 22, 82 benzodiazepine binding (rat), 22, 20 anthracycline molecule, 21, 196 receptor interactions (rat, rabbit, guinea pig, calf, human), 22, 250 Ca2-calmodulin complex, 22, 403 Thermotropic properties, dipalmitoylphosphatidylcholine, 22, 133 dopamine agonists (rat), 22, 281 Thiono-sulfur-containing compounds, effect on liver (rat), 21, 464 in ansamycins, 21, 394 Thrombin, platelet protein phosphorylation (human), 21, 422 picrotoxinin (mouse, guinea pig), 22, 444 Thymidine quantitative, 22, 725 kinase anxiolytic drugs, 22, 11 inhibition, 22, 231 molecular shape analysis, 21, 187 regulation, 22, 231 quantum chemical analysis, 22, 525 rescue effects in methotrexate-treated cells (human), 21, 718 transport sites, hypothalamic and striatal catecholamine uptake, 21, rescue, in methotrexate-treated cells (human), 21, 718 374 triphosphate, inhibition, 22, 231 Submandibular gland, regulation of autonomic receptors (rat), 21, 27 Thymidylate kinase, virus-coded, 21, 432 Substance P Thymidylate synthetase ‘25I-labeled derivative, binding to mesencephalic cells (mouse), 22,48 activity in L1210 ascites cells, 22, 760 receptors, in mesencephalic cells (mouse), 22, 48 blockers, 21, 224 Substituent constants, theorem, 22, 725 levels in gastrointestinal tumor cells (human), 21, 723 Substrate Thymus amine pump (rat), 21, 374 nuclear histones, effect of methylmercury(II) (calf), 22, 121 dopamine inhibition, in striatum and hypothalamus (rat), 21, 374 synaptosomal protein carboxymethyltransferase (calf), 21, 181 Subunit selectivity, in tetrameric hemoglobin (rabbit), 21, 1 Thyroid Succinimides, alkyl-substituted, structure-activity relationships cell (mouse, guinea pig), 22, 444 culture (porcine), 21, 66, 73 Sulfation rates, 7-hydroxycoumarin (rat), 22, 509 muscarmnic cholinergic receptors on (porcine), 21, 66, 73 Sulfhydryl group, effects on adenylate cyclase activation (dog), 22, 595 effect on cardiac muscarinic receptors (rat), 21, 589 Sulfidocyclophosphamide, cytotoxicity, synergism with misonidazole Thyrotropin-stimulated cyclic AMP, in cultured thyroid cells (porcine), (mouse), 22, 175 21, 66 Sulfite, horseradish peroxidase-hydrogen peroxide oxidation, 22, 732 Time delay, cyclic AMP accumulation in lymphoma cells, 22, 609 Sulfonamide, inhibition of skeletal muscle carbonic anhydrase (cat), Tissue, normal limiting (human), 22, 771 SUBJECT INDEX 829

Torpedo Vinblastine electric organ Ca2ttransport ATPase inhibition (human), 22, 413 drug interactions, 22, 63 effect on water flow in urinary bladder (toad), 21, 142 receptors, 22, 72 Vinca alkaloids, Ca2-transport ATPase inhibition (human), 22, 413 electroplax, receptors, 22, 82 Vincristine, Ca2-transport ATPase inhibition (human), 22, 413 Toxicity, see also Cytotoxicity Vindesine, Ca2-transport ATPase inhibition (human), 22, 413 cardiac, anthracydline antineoplastic agents (rabbit), 22, 471 Virus pulmonary, 4-ipomeanol (rabbit), 22, 738 herpes simplex, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyruridine, renal, phenacetin metabolites, 22, 479 21, 432 Toxin varicella zoster, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyuridine, bound molecules, exchange of tritium, 21, 343 21, 432 cholera Voltage clamp ADP ribosylation (mouse), 22, 204 effect on nicotinic acetylcholine receptor (frog, ray), 22, 82 effect on cardiac adenylate cyclase activity (rat), 22, 342 neuromuscular junction (frog), 22, 636 Temor, muscarinic agonist-induced (rat), 21, 594 Voltage-sensitive ion channels, nicotinic acetylcholine receptor, 21, 351 Triarylmethane dye, cytochrome P450-dependent reduction (rat), 22, 239 W

Trifluoperazine, effect on human platelets, 21, 422 Walker 256 carcinoma (rat), 21, 729 Tritium Warfarin back exchange, saxitoxin, 21, 343 -albumin interaction, equilibrium and kinetics, 21, 100 exchange, from bound toxin molecules, 21, 343 binding to human serum albumin, 21, 100 Tryptamine, effect on membrane fluidity, 22, 721 high-affinity binding sites, 21, 387 Tumor Water flow, in urinary bladder (toad), 21, 142 -derived methionine adenosyltransferases, differences in active-site and potential target (rat), 22, 752 x gastrointestinal Xanthines, binding in brain (rat, rabbit, guinea pig, calf, human), 22, cytotoxicity of 5-fluorodeoxyuridine and methotrexate (human), 250 21, 723 Xenograft thymidylate synthetase levels (human), 21, 723 colon adenocarcinoma (human), 22, 771 Tyrosine aminotransferase, hepatic, effect of pregnenolone- 16a-carbo- colon, selectivity (human), 22, 771 nitrile (rat), 21, 753 X-Ray, structure determinations Tyrosine hydroxylase chiorpromazine, 21, 409 effect on dopamine synthesis (rat), 21, 114 imidazolidines, 21, 400 induction by glucocorticoids (mouse), 22, 421 Xylamine chemical transformations in solution, 21, 380 U inhibition of norepinephrine uptake, 21, 380 Uptake, norepinephrine, inhibition by xylamine, 21, 380 Uracil, DNA incorporation, 21, 211 Y

Uterus, estrogen receptor (rat), 21, 533 Yohimbine “H-labeled V alpha2-adrenergic receptors, 21, 17 van’t Hoff plot, nonlinear, flunitrazepam (rat), 22, 20 binding in renal cortex (rat), 22, 532 Varicella zoster virus, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyrur- characterization of adenylate cyclase-coupled alpha-adrenergic idine, 21, 432 receptors (rat), 22, 589 Vas deferens use as radioligand (human), 22, 574 binding of $-endorphin, models (rat), 22, 657 histamine receptors (mouse), 22, 602 z Vasopressin, effect on urinary bladder (toad), 21, 142 Zinc, glucagon binding, 22, 105 U.S. POSTAL. SERVICE STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Rqulrsd by 39 U.S.C. 3685)

1. TiTLE OF PUBLICATION ISSN A. PUBLICATION NO. 2. DATE OF FILING Molecular Pharmacology J I 2 6 81 9 X 10/1/82

3. FREQUENCY OF ISSUE A. NO. OF ISSUES PUBLISHED B. ANNUAL SUBSCRIPTION . ANNUALLY PRICE Bi-monthly 6 Personal : $65.00 Institutional: $130.01

4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Stri(, City, County, Stat. and ZIP Cod.) (Not prlnts.rs)

9650 Rockville Pike Bethesda, Maryland 20814

5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS (Not prlnt#{149}fs) 9650 Rockville Pike Bethesda, Maryland 20814

t FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER. EDITOR. AND MANAGNG EDITOR (This Itn MUST NOT b. blank) PUBLISHER (Nama and CompIf#{149}MblIbsgAddr.sa) The American Society for Pharmacology 9650 Rockville Pike and Experimental Therapeutics Bethesda, Maryland 20814 EDITOR (Nan* and CompI. MailIng Addr.a) Dr. Norman Kirshner Duke University Medical School Pharmacology Department Durham, North Carolina 21202

MANAGING EDITOR (Nama ,d CompM(#{149} M&Ilng Addrass) Kay A. Croker, Executive Officer 9650 Rockville Pike American Society for Pharmacology & Experimental Therapeutics Bethesda, Maryland 20814 7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publica- tion is published by a nonprofit organization, its name and address must be stated.) (Item must be completed)

FULL NAME COMPLETE MAILING ADDRESS American Society for Pharmacoloqy 9650 Rockville Pike #{225}#{241}xperimenta I neraoeutics betnescia. Maryland Uli14

8. KNOWN BONDHOLDERS. MORTGAGEES, AND OTHER SECU RTY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS. MORTGAGES OR OTHER SECURITIES (It thr ar none, ao state)

FULL NAME COMPLETE MAILING ADDRESS

9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 411.3, DMM only) The purpose, funct,on. and nonprofit status of fhis organizafion and the exem t status for Federal income tax purposes (Check on.)

(1) (2) ri HAS NOT CHANGED DURING -- HAS CHANGED DURING (II changed, publlshr must submIt explanation of L.AJ PRECEDING 12 MONTHS U PRECEDING 12 MONTHS change with this statement.)

AVERAGE NO. COPIES EACH ACTUAL NO. COPIES OF SINGLE 10. EXTENT AND NATURE OF CIRCULATtON ISSUE DURING PRECEDtNG ISSUE PUBLISHED NEAREST TO 12 MONTHS FILING DATE

A.TOTALNO.COPIE5(Nifprsisflun) 2112 2175

8. PAID CIRCULATION 1. SALES ThROUGH DEALERS AND CARRIERS. STREET VENDORS AND COUNTER SALES none none

2. MAIL SUBSCRIPTION 1665 1782

C. TOTAL PAID CIRCULATION (Sum of 1081 and 12) i 665 1782

D. FREE DISTRIBUTiON BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY. AND OTHER FREE COPIES 86 75

E. TOTAL DISTRIBUTION (Sum ol C and 0) 1 7 5 1 1857

F. COPIES NOT DISTRIBUTED 1. OFFICE USE, LEFT OVER, UNACCOUNTED, SPOILED 36 1 318 AFTER PRINTING

RETURN FROM NEWS AGENTS none none

G. TOTAL (Sum of E. Fl and 2 - should equal net press run shown in A) 2 1 1 2 2175

SIGNATUR/AND TITLE OF EDITOR. PU8LISHER. BUSINESS 11. I certify that the statements made by’J MANAG , OR OWNER me above are correct and complete (( Q I

1 INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that shed significant light on drug action or selective toxicity at the molecular leveL The term “drug” is defined broadly to include chemical agents that selectively modify biological function.

Suitable papers are those which describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not regarded as appropriate for publication.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

“Short Communications” will be considered for rapid publication if their subject matter lies within the scope of the Journal, if they are concise, and if they are considered to be of sufficiently immediate importance to the work of other investigators to justify accelerated publication. They may contain experimental observations, theoretical material, or significant comment upon published investigations.

Page charges. Authors will be billed at the rate of $30.00 per mental Therapeutics. No reasonable request by the author for page after the paper has been published. It is expected that the page permission to reproduce any of his or her contributions to the charge will be paid if funds are available for that purpose from the journal wifi be refused. author’s institution or from the sponsor of this research. Payment of the charge is not a condition for publication. Neither the editors Organization and style ofmanuscripts. The policy of the Journal nor the reviewers will have knowledge as to who has paid the is to allow authors maximum freedom in organizing and presenting charge, and this payment always will be considered entirely volun- their material, and in expressing their ideas, provided only that tary. clarity and conciseness are achieved. Submission ofmanuscript. Manuscripts are published in English Certain conventions must be observed. Chemical and mathemat- only and should be sent to the Editor, Dr. Joel Hardman, Editor, ical formulas and abbreviations should follow the Instructions to Molecular Pharmacology, Department of Pharmacology, Authors ofthe Journal ofBiological Chemistry (Vol. 256, pp. 1-11, Vanderbilt University Medical Center, Nashville, Tennessee January 10, 1981). Drugs must be referred to by their generic or 37232, U. S. A. Manuscripts should be typewritten double-spaced chemical names throughout the text, but may be identified by trade with ample margins on one side of the paper, 8#{189}x 11 inches (ca. name in parentheses or a footnote. The systematic name and 215 x 280 mm). Submit four complete copies of the manuscript and number given by the Commission on Enzymes of the International four copies of each figure, plus one original drawing or photograph Union of Biochemistry should be included for each enzyme of of each figure. Each half-tone figure requires four original drawings importance in a paper, at the point in the Summary or Introduction or photographs. All pages should be numbered consecutively begin- where the enzyme is first mentioned. The use of abbreviations ning with the title page. Limit your reference listings to the minimal should be minimized and abbreviations avoided in the Summary. number required to adequately document the manuscript. In most All essential abbreviations should be defined in a single footnote instances 30 references or fewer should suffice. when first introduced. Abbreviations of journal names should con- Under usual circumstances reviewers will be instructed to return form to the style of BiologicalAbstracts. References to papers that only their comments to the editorial office and to destroy manu- have been accepted for publication, but have not appeared, should scripts after a fmal decision on their acceptability has been made. be cited like other references with the abbreviated name of the Original figures and single copies of manuscripts not accepted for journal followed by the words “in press.” Copies of such papers publication will be returned to the authors upon request. should be sent whenever the findings described in them have a It is understood that the manuscripts and the results they contain direct bearing on the paper being submitted for publication. “Per- will not have been published previously and are not being submitted sonal Communications” and “Unpublished Observations” should be elsewhere. Manuscripts are accepted for review with the under- cited in footnotes to the text and should not be included in the standing that all persons listed as authors have given their approval reference list. for the submission of the paper; further, that any person cited as a A manuscript should include the following, in the order listed: (1) source of personal communications has approved such citation. Title. Numbered footnotes to the title should be avoided; acknowl- Written authorization may be required at the Editor’s discretion. edgment of financial support should be given in an unnumbered Articles and any other material published in Molecular Pharma- footnote to the title. (2) Names of authors, their laboratory and cology represent the opinions of the author(s) and should not be institution. (3) A running title, not exceeding 60 characters and construed to reflect the opinions of the Editor(s) and the Publisher. spaces. (4) Summary. (5) Text. Footnotes should be referred to by If and when a manuscript is published, it will become the sole superscript numbers and references by numbers in parentheses. (6) property of the Journal. References, numbered according to order of citation in the text, Authors submitting a manuscript do so on the understanding that including title and complete pagination. Examples: 1. Goren, J. H., if it is accepted for publication, copyright in the article, including L. G. Bauce, and W. Vale. Forces and structural limitations of the right to reproduce the article in all forms and media, shall be binding of thyrotropin-releasing receptor: the pyroglutamic acid assigned exclusively to the Society for Pharmacology and Experi- moiety. Mol. Pharmacol. 13:606-614 (1977). 2. Sandler, M. Varia- tions in monoamine oxidase activity in some human disease states, should be at least 1.5 mm high. The figures must be ready, in all in Monoamine Oxidase and Its Inhibition. Ciba Foundation Sym- respects, for direct reproduction: no lettering or other art work will posium 39. Elsevier, Amsterdam, 327-340 ( 1976). (7). Footnotes, be done by the publisher. If symbols are not explained on the face numbered according to order of appearance in the text. (8) Tables. of the figure, only standard characters, of which the printer has (9) Figures. (10) Legends to figures. (11) Name and address of type, may be used (x, 0, #{149},El, , , A, C). The back of each person to receive galley proof. photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give Tables. These should be numbered with arabic numerals and captions and sufficient experimental detail, as required for tables. designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental Galley proof. The cost of all changes on galley proof, other than detail in a paragraph following the title to be intelligible without printer’s errors, will be charged to authors. The Editors are very references to the text (unless the procedure is given in the Methods much interested in having accepted contributions appear in the section, or under another table or figure). Footnotes to tables should earliest possible issue of the Journal, and therefore request that appear beneath the tables themselves and should be designated by galley proof be returned within 24 hours after its receipt. In excep- lower-case italic superscript letters, a, b, c, etc. tional cases, a “Note added in proof” may be attached and will be published if the Editor approves. Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only Reprints and page charges. An order form for reprints as well as the orignal set need be of quality suitable for reproduction except in information on the estimation of page charges will be mailed with the case of half-tones, which require four sets of photographs or galley proof. Please direct questions on reprints, page charges, or original drawings. These should be unmounted glossy photographs other business matters to Kay Croker, Executive Officer, American (or original India-ink drawings). Usually figures will be reduced to Society for Pharmacology and Experimental Therapeutics, 9650 one column width (85 mm) and all numbers after such reduction Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.